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From the
Desk of the
Residency
Program
Director

Welcome to the Forum!
It is bittersweet to write my final Message from the Program Director for the
Forum. This publication is one example of the passion, talent, creativity and
scientific inquisitiveness of our Jefferson residents. As a completely resident run
journal, what follows in this journal helps prove to me that the future of medicine
is in good hands.
In my time as program director, we have seen many changes in the healthcare
landscape, both nationally and locally at Jefferson. We have launched the
Milestone evaluations in the Next Accreditation System for the ACGME and are
embarking on major curricular reform at the UME level to better align training as
a continuum. We are having real and meaningful conversations about quality,
safety and value and thinking critically about those aspects of our care of patients.
Wellness is a concept that no longer only conjures yoga and crystals, but is taking
shape in our curriculum to train doctors who can cope with the difficult situations
they watch their patients endure every day and the stressors that being a physician
piles onto their lives. The new EMR is increasingly seeming like a reality and more
of our patients are insured and taking ownership of their health.
As I prepare for the next step in my career, I marvel at what our residents are
capable of and it makes my heart burst with pride when I watch them in action!
I will always strive to be a meaningful part of the education of our residents and
hope to continue to make Jefferson an ever stronger place to learn to practice
medicine. I leave you in good hands and you will all remain in a special place in
my heart for all we’ve been through together!
Never stop trying to be the best at what you do!
All the best,

Gretchen Diemer, MD, FACP
Associate Professor of Medicine
Program Director Internal Medicine
Associate Dean for GME and Affiliations

From the
Editors

Dear Students, Residents, Faculty, and Friends of the Forum,
We are excited to present you with the 16th annual edition of The Medicine Forum.
This work is a culmination of months of effort on the part of medical students, residents,
fellows and faculty to share clinical pearls from the last year of their experiences.
Amongst the greatest strengths of medical professionals and patients alike is the ability
to tell stories. Stories, and how they are told form the basis of medical care. The way
in which a particular patient's story unfolds has a lasting impact on physicians, trainees,
other medical staff, and perhaps most importantly, on future patients. Stories of patient
cases formed the earliest beginnings of evidence-based medicine. There is a Babylonian
tablet dating earlier than 6000 B.C.E. which describes a case of "dropsy", for the
instruction of patients of this condition.1 Stories told amongst practitioners of medicine
date back to the first published medical journal, the Acta Medicorum Berolinensium,
from Berlin in 1722.2
In today's era of information technology, the amount of information collected, analyzed
and reported in medicine is beyond the scope of any one physician to even be aware of,
let alone to read. In 2001 alone, the total number of articles indexed on MEDLINE was
over 400,000.3 Burgeoning topics in how the evidence base is gathered in medicine
include the use of Big Data analytic methods to provide patients and physicians with real
time data on outcomes as a tool of medical decision making. While these efforts are in
progress, the art and the science of medicine continue to rely upon experience from
patient stories, both our own, and from those of others.
In the Forum this year, we present a collection of stories, namely patient cases, which
highlight the process of differential diagnosis, novel associations, and medical decision
making. We would like to thank our contributors for their commitment to scholarship, our
editorial staff for their attention to detail, the Media department for the artistic expertise,
and the Department of Medicine for funding support. We hope you will enjoy reading
the stories presented here, and that they will be instructive in your future practice.
From the Editors-in-Chief,
Anusha G. Govind, MD
Loheetha Ragupathi, MD
Michael A. Valentino, MD, PhD
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A Case of Ipilimumab Induced Hypophysitis
Eric Shiffrin, MD and Melinda Ukrainski, MD

Figure 1. Postcontrast T1-weighted magnetic resonance image
of the brain two days prior to the fourth dose of ipilimumab and
hospital admission, demonstrating diffuse enlargement of the
pituitary gland (arrow).

INTRODUCTION
Ipilimumab (Yervoy®) is a human monoclonal antibody
that has been shown to significantly improve survival
in cases of metastatic melanoma.1 Ipilimumab blocks
cytotoxic T-lymphocyte antigen 4 (CTLA-4), a protein
receptor on the surface of T-cells, resulting in their
activation, proliferation and an anti-tumor response.2,3,4
Commonly reported immune-related side effects of
ipilimumab are enterocolitis, dermatitis, and hepatitis.5,6,7
However, different endocrinopathies, including
autoimmune hypopituitarism, have become emerging
clinical entities in patients taking ipilimumab. We present
a case of ipilimumab induced hypophysitis in a 62-yearold male presenting with fatigue and hypotension.

CASE PRESENTATION
A 62-year-old male with a history of melanoma metastatic
to the lung and brain status-post frontal craniotomy and
whole brain radiation, as well as a recent diagnosis of
hypothyroidism, presented from the oncology office with
hypotension after receiving his fourth dose of ipilimumab

Figure 2. Postcontrast T1-weighted magnetic resonance image of
the brain three months before presentation and prior to starting
ipilimumab, demonstrating normal pituitary gland architecture
and size (arrow).

therapy. The patient had a routine blood pressure check
after the chemotherapy infusion and was found to be
hypotensive at 80/58 mmHg. He reported increasing
fatigue over the past week. He denied chest pain,
shortness of breath, dizziness and headache. He was
given one liter of normal saline solution, but remained
hypotensive and was directly admitted to the hospital.
On physical exam, the patient was tachycardic to 102
beats per minute with a regular rhythm, clear lungs, and
positive orthostatics. Laboratory studies were significant
for a thyroid stimulating hormone of <0.02 uIU/mL
(normal range = 0.3 – 5 uIU/mL), free T4 of 1.2 ng/dL
(normal range = 0.7 – 1.7 ng/dL), follicle stimulating
hormone of 0.9 mIU/mL (normal range 1.5 – 12.4 mIU/mL),
adrenocorticotropic hormone (ACTH) of <9 pg/mL (normal
range 9 – 46 pg/mL), total testosterone of 4 ng/dL (normal
range 250 – 1100 ng/dL, and a free testosterone of
0.4 pg/mL (normal range 35 – 155 pg/mL). His white blood
cell count, hemoglobin and electrolytes were within
normal limits. A noon cortisol was 0.3 mcg/dL (normal
A.M. range 16 – 20 mcg/dL and P.M. range 2 – 12 mcg/dL)
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and a subsequent cosyntropin stimulation test with 250 µg
of cosyntropin resulted in cortisol values of 5.4 mcg/dL
and 8.8 mcg/dL at one hour and two hours respectively.
An a magnetic resonance image (MRI) of the brain with
and without contrast performed two days earlier for
surveillance of his known brain metastases was reviewed
on admission and revealed diffuse enlargement of the
pituitary gland (Figure 1). This finding was new compared
to an MRI performed three months earlier, prior to
starting ipilimumab (Figure 2). The patient had no family
history of endocrine disorders.

DISCUSSION
Endocrine-related adverse events were reported in 8.5%
of patients in a recent phase III trial designed to evaluate
ipilimumab as an adjuvant therapy following resected
stage III melanoma, with hypophysitis encompassing
5.1% of these events.8 The majority of patients who
develop hypopituitarism do so after the third or fourth
dose of ipilimumab, suggesting a possible cumulative
effect.1,3 Adverse events have limited the duration of
use of the drug in patients who could have clinical
benefit from additional therapy.
The mechanism of hypopituitarism is likely from
ipilimumab’s immunomodulatory effect on activating
T-cells, resulting in a lymphocytic hypophysitis.2,3,5,6 It
has also been shown that some pituitary cells express
CTLA-4, the receptor target of ipilimumab.9 Therefore, it
remains unclear whether the adverse effects are caused
by T-cells acting against antigens shared by tumor cells
and normal cells or from a direct antibody effect on
CTLA-4 receptors on pituitary cells, or both. Presenting
symptoms are related to a pituitary mass effect and
consequent hormone deficiencies.5,7,10 Clinical manifestations may be non-specific as they depend on the
extent of hormone deficiencies. Additionally, it is
often difficult to recognize many of these symptoms
in patients undergoing chemotherapy, but there should
be a low threshold to consider hypophysitis in a patient
taking ipilimumab. Typical symptoms include fatigue,
headache, and loss of libido. 10 Other symptoms
could include cold intolerance, visual disturbances,
hypotension, hypoglycemia and hyponatremia. Our
patient reported fatigue, but his diagnosis only became
apparent after hypotension was noted.
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MRI findings in ipilimumab-induced hypophysitis are
non-specific and are typically characterized by a diffuse
enlargement and homogeneous enhancement of
the pituitary gland. Less commonly, heterogeneous
enhancement has also been described.10-11 While it is
common to have radiographic evidence of hypopituitarism, a normal MRI is possible. Follow-up imaging
often shows resolution of abnormal findings after
hormone replacement.11
Pituitary hormone replacement with corticosteroids is
critical to treatment, assuming ACTH is low. Either high
dose or physiologic replacement dose corticosteroids
are needed. Current recommendations advocate for
high dose (1-2 mg/kg/day of prednisone or equivalent)
steroids for moderate to life threatening symptoms.12
However, it is not clear whether initial high doses of
corticosteroids are beneficial in treating hypophysitis.
While they may play a role in reducing inflammation, they
do not improve neuro-endocrine function compared
to physiologic doses. However, high doses of corticosteroids may increase morbidity through side effects.3, 13
Mineralocorticoid replacement is not needed since the
renin-angtiotensin-aldosterone system is still intact. It
should be at the discretion of the oncologist and endocrinologist as to whether ipilimumab should be continued
based on the condition of the patient and response
to hormone replacement. Hormone deficiencies can
improve, although corticotroph function seems to be
the least likely to recover.14 Many doctors recommend
close monitoring for hormone abnormalities in patients
receiving ipilimumab, especially after the third infusion.

KEY POINTS
Hypophysitis is a well recognized side effect of
ipilimumab therapy. A high clinical suspicion for hypopituitarism in patients receiving the drug is imperative
due to the non-specific symptoms and potentially
life threatening consequences. Corticosteroids
should be promptly initiated as soon as secondary
adrenal insufficiency is detected. While ipilimumab
has many side effects, the drug has improved survival
in metastatic melanoma and remains an important
treatment option.
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Into The Woods by Ashish Shah, MD

The Medicine Forum | 7 5

A Special Case Of A Broken Heart
Shuwei Wang, MD

Figure 1. Mrs. S's initial EKG showing ST segment elevations in leads V2-V6.

INTRODUCTION
Takotsubo cardiomyopathy (TC), also known as
stress cardiomyopathy, and broken heart syndrome
is characterized by transient left ventricular (LV) apical
akinesis with symptoms mimicking acute coronary
syndrome. The first case was described by Sato et al.
in Japan.1 The Japanese word “takotsubo” translates to
“octopus pot” describing the shape of the left ventricle
during systole. TC can be triggered by a “broken heart”
including death of a loved one, constant anxiety,
surgery, or critical illness etc. Prevalence is around 2%
to 3% with over 90% in postmenopausal women aged
between 58 and 75. Its pathogenesis remains unclear.
Some postulated that excess catecholamine released
during stress can induce an exaggerated sympathetic
response precipitating severe, reversible LV dysfunction
in patients without coronary disease.2 Whether there is a
genetic component is not well understood. There are a
few reported cases of Takotsubo in family members, one
case of two sisters and another mother-daughter pair.3,4
Recurrence of the syndrome in the same patient, although
rare, can occur and suggests a genetic predisposition.5
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Majority of patients regain normal ventricular function
within one to four weeks if they survive the acute episode.
Hospital mortality rates range from 0 to 8 %. However,
one major complication is the risk of intraventricular
thrombus formation and systemic embolization. Data
is lacking to guide anticoagulation for LV thrombus
prevention in patients with stress cardiomyopathy.

CASE PRESENTATION
Mrs. S is a 62 year old woman with a prior history of TC
with full recovery, hyperlipidemia, and gastroesophageal
reflux disease presented with chest pain radiating to her
left shoulder. She was under significant financial stress
during that week. Her pain was unrelieved with aspirin
or sublingual nitroglycerin. In the emergency room, her
electrocardiogram showed ST segment elevations in
leads V2-V6 (Figure 1) with Troponin T 1.49ng/mL. She
was immediately started on heparin and nitroglycerin
drips and rushed to the catheterization laboratory.
Coronary angiography did not reveal significant coronary
disease but incidentally found elevated pulmonary

wedge pressures. Upon transfer to the cardiac intensive
unit, Mrs. S became hypotensive and norepinephrine
was started. Her transthoracic echocardiogram (TTE)
revealed moderately decreased LV systolic function
with an estimated ejection fraction (EF) of 35%, with
segmental wall motion abnormalities, mid and distal
akinesis of the LV and hyperkinesis of basal LV. There was
a late-peaking LV outflow tract gradient of 77 mm Hg
consistent with severe, dynamic left ventricular outflow
tract (LVOT) obstruction.

DISCUSSION

She had a prior episode of TC when her husband passed
away three years ago. She also has a twin sister who
suffered from TC a year ago when she lost her job.
Unlike Mrs. S, she did not fully recover and required long
term heart failure management.

Familial cases of stress cardiomyopathy are very rare.
One case reports a 64 year old female diagnosed with
TC when presented with sudden chest pain, elevated
cardiac enzymes and ST elevations. Her elder sister
developed TC one year prior with similar presenting
symptoms. There are also several other reports of
sisters with TC. Studies on genetic polymorphisms for
Takotsubo have been inconclusive. One study found an
association between patients with TC and beta 1 adrenoreceptor gene polymorphisms, suggesting possible
genetic disease modifiers for developing TC.6 However,
a large Australian study did not find any association
between functional variants in the G-protein-coupled
receptor kinase 5 genes or the β1-adrenergic receptor
with the occurrence of the syndrome7.

DIFFERENTIAL DIAGNOSIS
Takotsubo was at the top of our differential given the
patient’s personal and family history and recent financial
stress. The lack of significant coronary disease on LHC
clinched the diagnosis of stress cardiomyopathy.

OUTCOME AND FOLLOW-UP
Mrs. S was diagnosed with TC with LVOT obstruction
complicated by cardiogenic shock. The LVOT obstruction
made treatment particularly difficult given that inotropes
can worsen the obstruction. Due to tachycardia, she
was switched from norepinephrine to phenylephrine.
On day 2, Mrs. S developed hypoxia and was intubated
and rushed to cath lab for intra-aortic balloon pump
insertion. However, the procedure was aborted when
her right heart catheterization numbers and vital signs
improved. She continued to recover on supportive care
and was successfully extubated on day 8. Her repeat
TTE showed recovery of systolic function (EF 70%) but
revealed a 2.3 x 1.1 cm LV apical thrombus. Heparin drip
and warfarin were initiated. On day 9, patient reported
blurry vision and a left visual field defect that were
persistent despite wearing her glasses. Although her
head CT scan was negative for mass effect or stroke,
her head MRI revealed a recent punctate infarction in
the right occipital lobe. In addition, on day 11, Mrs. S
developed intractable back pain and a CT Abdomen and
Pelvis showed new wedge-shape perfusion defects in
the right kidney consistent with infarcts.

This case has multiple teaching points. First, it is one
of the few cases of a patient with a recurrence of
Takotsubo as well as a twin sister who suffered from the
same syndrome suggesting a possible genetic predisposition to stress cardiomyopathy. Second, it emphasizes
the risk of intraventricular thrombus formation and
systemic embolization in patients with TC and raises the
important discussion on whether these patients should
receive prophylactic anticoagulation.

More research is also needed to understand the risk
and prevention of thromboembolism in TC patients.
In a Japanese study of 21 patients with Takosubo, they
found that 3 patients (14%) suffered thromboembolism,
one of which had a LV thrombus. They recommended
prophylactic anticoagulation for TC patients with severe
wall motion abnormality to prevent cardioembolic stroke8.
There are scant data on criteria for prophylactic anticoagulation to prevent thromboembolism in TC. In patients
with myocardial infarction, it has been found that
reperfusion therapy and anticoagulant therapy lowers the
risk of thrombus formation, which would also lower the
risk of thrombus embolization. In a 1993 meta-analysis
in patients who had an anterior MI, the odds ratio of LV
thrombus in patients treated with fibrinolytic was half
compared to no fibrinolytic therapy.9 The same study
also showed that initiating heparin early and for more
than 48 hours lowered the rate of thrombus formation.
In a randomized control trial, high dose (12,500 units)
subcutaneous unfractionated heparin given every 12
hours for 10 days was associated with lower incidence
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of LV thrombus compared to low dose (5,000 units).
(11 versus 32 percent).10 Amongst patients who already
developed a LV thrombus, anticoagulation with
warfarin lowers the risk of thrombus embolization. An
observational study of 43 patients with LV thrombus after
MI found no embolic events in the 25 patients treated
with anticoagulation compared to 7 of 18 untreated
patients having an embolic event, all occurring within
4 months. 11 Although no studies have been done
on patients with stress cardiomyopathy, it would be
reasonable to initiate anticoagulation in patients with
severe LV dysfunction to prevent thrombus.

KEY POINTS
1. Familial and recurrent cases suggest a genetic
predisposition to Takotsubo cardiomyopathy.
2. Patients suffering from stress cardiomyopathy with
severe LV dysfunction may benefit from early anticoagulation to prevent thromboembolism.
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Acute Respiratory Distress Syndrome from Tick-borne
Human Granulocytic Anaplasmosis Infection
Vedang Patel, MD

INTRODUCTION
Tick-borne infections were first formally recognized over
a century ago, but it was only in 1990 that the first case
of human granulocytic anaplasmosis (HGA), a tick-borne
infection caused by Anaplasma phagocytophilum, was
identified.1,2 Like other tick-borne infections, HGA presents
as a nonspecific febrile illness. The most common clinical
features are fever, headache, myalgia and malaise.2 This
case report presents a rare but serious complication of
HGA – acute respiratory distress syndrome (ARDS).

CASE PRESENTATION
A 49-year-old female with no past medical history
presented to her local emergency department with
complaints of fevers, headache, neck pain, myalgia,
and malaise. She denied symptoms of upper respiratory
tract infection, diarrhea, dysuria, rashes, and bleeding or
bruising. She worked as an administrative assistant and
lived on a farm in a rural area of Pennsylvania. She was in
a monogamous relationship. She drank alcohol socially,
and she was not known to use any illicit drugs.
Her vital signs were temperature of 102 degrees Fahrenheit,
pulse of 100 beats per minute, oxygen saturation of 98%
on room air, and respiratory rate of 18 breaths per minute.
On physical examination, she appeared fatigued but was
alert and oriented to person, place, and time. There were
no focal neurologic deficits. Her oropharynx was clear.
Her neck was supple with full range of motion. Brudzinski
and Kernig test were negative. Her lungs were clear to
auscultation. Cardiac exam revealed tachycardia but no
murmurs, rubs, or gallops. Her abdomen was soft and
non-tender. There were no stigmata of liver disease. She
had no rashes and no cutaneous bleeding. There were
no palpable lymph nodes.
Laboratory evaluation revealed a white blood cell count of
2 x109/L (normal range = 4-11 x109/L), platelet count of 43
x109/L (normal range = 140-400 x109/L), and hemoglobin
of 11 g/dL (normal range = 14-17 g/dL). Her liver function
panel revealed an aspartate aminotransferase (AST) of 923
U/L (normal range = 7-42 U/L) and alanine aminotrans-

ferase (ALT) of 946 U/L (normal range = 1-45 U/L). Her
bilirubin and alkaline phosphatase were mildly elevated.
The patient was admitted for Systemic Inflammatory
Response Syndrome (SIRS). She was empirically started
on vancomycin and piperacillin-tazobactam. On her first
day of admission she developed hypoxemic respiratory
failure. A chest x-ray showed bilateral airspace opacities
without evidence of volume overload. Mechanical
ventilation was initiated and doxycycline was added. She
was transferred to Thomas Jefferson University Hospital
for management of ARDS.

DIFFERENTIAL DIAGNOSIS
The patient's high fevers and acute onset of symptoms
suggested an infectious etiology. Cerebrospinal fluid
testing was negative for viral, fungal, and bacterial
pathogens. Bronchoalveolar lavage was lymphocytepredominant, and testing for viral, fungal, and bacterial
respiratory pathogens was also negative. A right upper
quadrant abdominal ultrasound was unremarkable.
Given that she lived on a farm with deer nearby and the
laboratory findings of leukopenia, thrombocytopenia,
and elevated liver enzymes, there was concern for a
tick-borne infection. Blood tests for Lyme, Ehrlichia,
Babesia, and Rocky Mountain Spotted Fever (RMSF)
were negative. Serum IgM and IgG for Anaplasma
were negative, but Anaplasma DNA testing via real time
polymerase chain reaction (PCR) was positive.

OUTCOME AND FOLLOW-UP
The patient was ventilated per the ARDS protocol, with a
tidal volume of 6 mL/kg. Once the diagnosis of HGA was
confirmed, vancomycin and piperacillin-tazobactam were
discontinued and doxycycline, the treatment of choice
for Anaplasma, was continued. After three days in the
medical intensive care unit the patient was successfully
extubated. At the time of discharge her blood cell counts
had normalized and her liver enzymes were improving.
Her chest x-ray demonstrated resolution of the bilateral
airspace opacities. The patient was discharged home to
complete a 14-day course of oral doxycycline.
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DISCUSSION
HGA is characterized by a febrile illness that most often
presents with headache, myalgia, and fatigue. The first case
of HGA in a human was in 1990 when a Wisconsin man
died two weeks after being bitten by a tick. In the United
States, the Centers for Disease Control and Prevention
has recorded 2135 cases between 1994 and 2002, the last
year for complete data.2,3 The incidence of HGA is rising
and cases are often unreported. ARDS, the most serious
complication seen in this patient's clinical course, has been
reported in less than 1% of cases of HGA.4
ARDS is characterized by hypoxemic respiratory failure,
radiographic evidence of bilateral airspace opacities
without volume overload, and an arterial oxygen
pressure (PaO2) to inspired oxygen fraction (FiO2) ratio
of less than 300 mmHg. Sepsis, aspiration, pneumonia,
and trauma are the most common causes of ARDS.5,6
Patients require high levels of oxygen supplementation
during the first several days, and clinical improvement
usually depends on treatment of the underlying cause.
Unlike traditional mechanical ventilation strategies that
use 10 to 15 mL/kg of tidal volume, a low tidal volume
approach of 6 to 8 mL/kg has been shown to decrease
mortality and improve clinical outcomes in patients with
ARDS.6 The consequences of ARDS include impaired gas
exchange, decreased lung compliance, and pulmonary
hypertension.7 Thus, it is imperative to make a diagnosis
of the underlying cause and to begin immediate treatment.
The diagnosis of HGA is often difficult because symptoms
develop days after the tick bite but seroconversion takes 2
to 4 weeks. If testing for antibodies is being considered,
2 serum samples should be taken at least 2 to 3 weeks
apart and a 4-fold rise in antibody titer is needed to make
the diagnosis. A Wright- or Giemsa-stained peripheral
blood smear may provide early diagnosis by detecting
morulae in neutrophils.2 Confirmation of HGA now often
relies on PCR testing. but PCR is not readily available at all
facilities. Therefore diagnosis often relies on clinical signs
and symptoms, and treatment should not be delayed
for confirmation of diagnosis. HGA infection is most
common in the spring and summer months. The vector
for transmission is the deer tick Ixodes scapularis.1 The
highest incidence in the United States is in the northeast
and north central states. Laboratory findings suggestive of
HGA are leukopenia (present in 50% of cases), thrombocytopenia (94%), and transaminitis (90%).2 This patient

12 | The Medicine Forum

5

had all of the common laboratory features, presented in
late spring, and lived in the northeast United States.
The treatment of choice for adults with HGA is
doxycycline at a dose of 100 mg orally every 12 hours
for 7 to 14 days. In patients who are pregnant or have a
tetracycline allergy, rifampin at 300 mg twice daily may
be substituted.2,8 Symptoms start to resolve within 24
to 48 hours, and in patients who do not show clinical
improvement a co-existing Babesia infection should be
considered.2 Treatment with doxycycline and a low tidal
volume mechanical ventilation strategy were pivotal to
this patient's favorable outcome.

KEY POINTS
Headache, myalgia, and fatigue are the most common
symptoms of HGA. Seroconversion takes two weeks so
PCR testing is the test of choice for diagnosis. If suspicion
for HGA is high, treatment with doxycycline should not
be delayed for confirmation of diagnosis. ARDS is a very
rare complication of HGA. Treatment with doxycycline
and a low-tidal volume mechanical ventilation strategy
were essential for the favorable outcome in this patient.
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Chronic Idiopathic Intestinal Pseudo-Obstruction:
A Working Diagnosis
Ankush Kalra, MD and Anthony J DiMarino, MD

INTRODUCTION
Chronic intestinal pseudo-obstruction (CIP) is a
rare and disabling motility syndrome, yet one that
demands an extensive review of digestive motility and
peristaltic pathophysiology. Primarily a disorder of the
small intestine, CIP was first described by Dudley and
colleagues in 1958; it is defined by severe signs and
symptoms of intestinal obstruction (abdominal pain
and distention, nausea, vomiting, and constipation), in
addition to radiographic evidence of dilated bowel in the
absence of a true, mechanical obstruction. Symptoms
are often slowly progressive and diagnosis requires the
presence of symptoms for at least six months.1 A 2013
national survey in Japan estimated the prevalence of
CIP at 0.8 to 1.0 per 100,000, with an incidence rate
of 0.21 to 0.24 per 100,000. In the same survey, the
mean age at diagnosis is 63.1 years for males and 59.2
for females.2 CIP encompasses an extensive differential
diagnosis, a complex, multidisciplinary work-up, and
a vast array of potential treatment options based in
intricate pathophysiology.

CASE PRESENTATION:
RC is a 75-year-old male who presented with recurrent
small bowel obstructions (SBOs) between August and
September 2014. He has no chronic medical conditions,
and his past medical history is significant only for a
community-acquired pneumonia and pleural empyema
at age 50. His surgical history is significant only for a right
inguinal hernia repair at age 7. Initially, his symptoms
began in April 2014 and were mild, limited to constipation
relieved with over the counter laxatives. After two brief
admissions for SBOs that resolved with nasogastric tube
decompression, RC presented on September 9, 2014
with a distended, tympanitic abdomen with absence
of bowel sounds and minimal tenderness to palpation.
A computed tomography (CT) scan demonstrated
multiple dilated loops of small bowel with a transition
point in the proximal ileum. A nasogastric tube was
again placed but the obstruction persisted clinically and
on repeat X-Rays. During an exploratory laparoscopy
on September 15, 2014, the right colon and entire small

bowel were palpated. No transition zone or small bowel
abnormality was found and the peritoneal surfaces of
all abdominal organs appeared normal. Ultimately, an
ileocecectomy was performed and RC underwent a
thorough diagnostic workup.

DIFFERENTIAL DIAGNOSIS:
While CIP is a rare and elusive diagnosis, it is not one of
exclusion. It is a clinical diagnosis typically confirmed
by endoscopic or radiologic exclusion of a mechanical
obstruction. In the case of RC, the lack of mechanical
obstruction was confirmed by manual palpation of the
entire small bowel and colon. The rest of the workup
focused on the etiology of CIP, which may be either
idiopathic or secondary. Secondary CIP was ruled out
with lab testing for collagen vascular diseases, hypothyroidism, diabetes, porphyria, and celiac disease, as well
as a lack of any iatrogenic factors. A thorough paraneoplastic work-up was unremarkable; Ho, Yu, and neuronal
nuclear antibodies were negative, CT scan of the thorax
ruled out thymoma, thyroid ultrasound revealed benign
nodules, and testicular ultrasound demonstrated no
masses. The ileocecectomy specimen demonstrated
small bowel mucosa with prominent reactive lymphoid
hyperplasia. While nonspecific, this pathology is most
consistent with an inflammatory neuropathy.

OUTCOME/FOLLOW-UP:
An exploratory laparotomy performed on September
24, 2014 demonstrated significantly dilated small bowel
at the ligament of Treitz. There was no evidence of
mechanical obstruction such as mass, adhesions,
stricture, kinking, or intussusception. Palpation of
the colon was normal minus significant transverse
colon dilation. Ileocecectomy was performed and a
gastrostomy tube was also placed for venting. With
continued symptoms and radiographic pseudoobstruction after ileocecectomy, RC was started on total
parenteral nutrition (TPN). After failure of stool softeners,
laxatives, and prokinetic lubiprostone, treatment with
prokinetic linaclotide was initiated. Moderate success
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was achieved with the addition of somatostatin analog
octreotide and antibiotic rifaximin, as RC began to move
his bowels. Acetylcholinesterase inhibitor neostigmine
was also administered with successful movement of the
bowels within less than five minutes, further supporting
a neuropathic etiology. Ultimately, RC was discharged
on October 14, 2014 with linaclotide, octreotide,
polyethylene glycol, and TPN. Significant progress was
made over the ensuing months, as he began to tolerate
oral intake, discontinued TPN, and had his medications
tapered. Currently, RC only takes linaclotide twice
weekly and maintains a gastrostomy tube for intermittent
venting. He has returned to his normal lifestyle and has
daily, formed bowel movements without symptomatic
or radiographic evidence of bowel obstruction.

DISCUSSION:
Reflecting on the case of RC, it can be said that the true
mechanism of his return to health remains uncertain.
CIP is classified using three histological categories:
neuropathies (either inflammatory or degenerative),
myopathies (smooth muscle fibrosis), and mesenchymopathies (dysfunction of the pacemaker interstitial
cells of Cajal). Inflammatory neuropathies are the most
common cause of CIP, defined by myenteric plexus
ganglionitis and encompassing etiologies such as
paraneoplastic syndromes, infections, and connective
tissue disorders. 1 Interestingly, most case reports
describe CIP as the first presentation of another disease,
most commonly small cell lung cancers, lupus, and
scleroderma. 3 While the appropriate screening tests
were done for these conditions, one 2012 case report
describes CIP as the initial manifestation of an atypical,
seronegative systemic sclerosis.4 Octreotide has been
used with much success in CIP secondary to scleroderma.
Gastrointestinal transit studies have demonstrated that,
while octreotide has been proven to slow intestinal transit
by inhibiting intermittent, low-amplitude contractions, it
enhances short burst, high amplitude contractions.5 A
1991 study demonstrated that scleroderma patients with
an inability to generate migrating motor complexes were
able to produce 3.6 complexes every three hours after
administration of 100 micrograms of octreotide.6 The
stasis associated with CIP is believed to generate a cycle
of small intestinal bacterial overgrowth (SIBO) that leads
to mucosal inflammation and further dysmotility1, and
this might explain why RC developed transverse colon
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dilation later on in his course. While rifaximin and other
antibiotic regimens are often used to treat SIBO, it has
been demonstrated that 50 micrograms of octreotide
every evening for three weeks will reduce breath
hydrogen excretion, a marker of SIBO, from 25 to 4 parts
per million.6 Therefore, the SIBO that is both a contributor
to and consequence of CIP may be successfully treated
by targeting small intestinal motility. As CIP generally has
a chronic, relapsing course and overall poor prognosis,
it is important to regularly monitor these patients and
remain vigilant about pursuing further workup and
therapies with any change in clinical status.

KEY POINTS:
The case of RC is a complicated one defined by
uncertainty and a multitude of diagnostic and therapeutic
interventions. While he is currently symptom free and
maintained only on linaclotide twice weekly, history
tells us that this case may soon be revisited and a more
certain diagnosis obtained. While there is a need for
physicians to become knowledgeable about CIP, the
medical community must continue to inquire about
targeted therapies. It is essential that these stories be
shared. The pathophysiological basis of treatments used
in these cases continues to be a key focus of research.
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Eculizumab for Gemcitabine-Induced Hemolytic
Uremic Syndrome: A Novel Therapy for an
Emerging Condition
Raphael Karkowsky, MD and Kinjal Parikh, MD

Figure 1. Microscopic appearance of peripheral blood smear from
patient (×100), showing increased schistocytes, echinocytes, and
acanthocytes

Figure 2. Microscopic appearance of bone marrow biopsy from
patient (×20), showing hypercellular bone marrow with trilineage
hematopoiesis and no evidence of dysplasia or metastatic disease

INTRODUCTION

of 420 IU/L (reference range 125-240 IU/L), undetectable
haptoglobin, and the presence of schistocytes on the
peripheral smear (see Figure 1). Creatinine was elevated
to 2.8 mg/dL (reference range 0.7-1.4 mg/dL) and an
ADAMTS-13 (A disintegrin and metalloproteinase with a
thromboSpondin type 1 motif, member 13) returned as
normal. The patient was diagnosed with gemcitabineinduced aHUS. Gemcitabine was discontinued, and
the patient was started on steroids. Two weeks later,
he presented with generalized tonic-clonic seizures,
uncontrolled hypertension, and worsening renal failure.
His labs on admission showed continued hemolysis and
thrombocytopenia. In light of the patient’s poor response
to steroids, the decision was made to start eculizumab.

Atypical hemolytic uremic syndrome (aHUS), a
thrombotic microangiopathy (TMA), is a disease
characterized by hemolytic anemia, thrombocytopenia,
and renal impairment. Gemcitabine, a commonly used
chemotherapy, is emerging as a cause of aHUS. Although
rare, the morbidity and mortality can be significant.
Few studies have explored the use of eculizumab, an
anti-C5 monoclonal antibody as a potential therapy for
gemcitabine-induced aHUS.

CASE PRESENTATION
A 45 year old Caucasian male with metastatic urothelial
carcinoma was started on weekly gemcitabine (1000
mg/m2 per dose) to treat recurrent disease. During his
seventh cycle, he was hospitalized for hypertension,
acute kidney injury, and anemia. Laboratory data at
that time revealed a hemoglobin of 6.2 g/dL (reference
range 14.0-17.0 g/dL) and a platelet count of 70 x 109/L
(reference range 140-400x 10 9/L). Hemolysis was
suggested by an elevated lactate dehydrogenase (LDH)

DIFFERENTIAL DIAGNOSIS
Gemcitabine-induced aHUS is often a difficult diagnosis
to make. In this case, it was distinguished from thrombotic
thrombocytopenic purpura (TTP) by normal levels of
ADAMTS-13. Furthermore, normal coagulation studies
and the lack of bleeding made disseminated intravascular
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coagulation unlikely. Bone marrow biopsy showed
trilineage, hypercellular hematopoiesis, suggesting
peripheral destruction rather than myelosuppression
from chemotherapy (see Figure 2). Idiopathic thrombocytopenic purpura was a less likely diagnosis, as the
presence of schistocytes suggested microangiopathy.

OUTCOME AND FOLLOW-UP
The patient was started on eculizumab and received a
course of six doses. His treatment was complicated by
a multifocal pneumonia that developed four days after
receiving his second dose. His labs two months after
starting treatment showed an improved platelet count
of 118 x 109/L. Although he remained anemic, his labs
did not show evidence of further hemolysis (see figure
3). The patient’s creatinine remained elevated at 6.2 mg/
dL, and he was started on renal replacement therapy
(RRT). The patient died three months after initiation of
eculizumab therapy secondary to complications of his
underlying malignancy.

DISCUSSION
The vast majority of HUS are preceded by a bout of
infectious diarrhea, usually due to Escheria coli; 90% of
cases are not, and are therefore termed atypical.1 This
atypical form of HUS is associated with factors such as
human immunodeficiency virus infection, malignancy,
organ transplantation, pregnancy, or medications,
including anti-neoplastic drugs.1,2 Recently, gemcitabine,
a 2`,2`-difluorodeoxycytidine, has surfaced as a cause
of atypical HUS. The incidence of gemcitabine-induced
aHUS ranges from 0.015 to 1.4%2 per current case series
reviews.
Pathologically, aHUS is identical to the typical form.
Histology generally shows arteriole and capillary
thickening, a swollen endothelium, and proteinaceous
deposits in the subendothelium. A blood smear will
typically show schistocytes. The kidneys are most
commonly involved, but the brain, lung, pancreas,
and gastrointestinal tract may be affected as well.
Dysregulation of the alternative complement cascade
leads to the formation of the final membrane-attack
complex (MAC) and subsequent endothelial injury,
which plays a pivotal role.1
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Figure 3. Chart Showing response to eculizumab treatment in
gemcitabine-induced thrombotic microangiopathy. Red arrows
represent eculuzimab administration and blue arrows represent
gemcitabine administration.

The most agreed upon treatment for gemcitabineinduced aHUS remains discontinuation of the drug.
Other therapies, such as therapeutic plasma exchange
(TPE), demonstrate less reliable effectiveness, as shown
in a recent meta-analysis by Gore and colleagues, which
concluded that the use of TPE is not associated with
an improved rate of recovery.8 Recent case reports
have also suggested a potential role for splenectomy8 or
rituximab.7 Novel therapies such as Complement Factor
H, a regulatory protein in the alternative complement

cascade, is currently being studied as a treatment for
patients suffering from aHUS who are deficient in this
protein.1
The safety of eculizumab is still being determined. In
this case, the patient developed multifocal pneumonia
just days after receiving his second dose of eculizumab.
Inhibition of MAC formation by eculizumab reduces
defense against encapsulated organisms, specifically
those that cause pneumonia.10 Therefore, it is reasonable
to suspect, that eculizumab may have served as a risk
factor in our patient’s development of this complication.
Only a few studies have investigated the treatment of
gemcitabine-induced HUS with eculizumab. Similar
to the studies by Starck and colleagues and Legendre
and colleagues, this case study highlights eculizumab’s
effectiveness in improving microangiopathy and the
resultant thrombocytopenia and hemolysis in aHUS.
Those studies, although promising, were somewhat
confounded by prior use of TPE, which was not true in
our case. Lohr and colleagues’ case series, seemed to
suggest that eculizumab is an effective therapy for the
kidney damage sustained in aHUS. In our case study,
however, the patient did not demonstrate the same
improvement in kidney function, and his kidney disease
ultimately progressed to the point of needing RRT. The
role of eculuzimab in treating aHUS and its efficacy is
still being defined.

KEY POINTS
The above case demonstrates eculizumab’s partial
effectiveness in treating the microangiopathy in
gemcitabine-induced aHUS. Although the patient
demonstrated recovery in platelet count and resolution
of his hemolysis, he showed only limited improvement
in renal function. Moreover, the patient’s course of
therapy was complicated by pneumonia, which along
with infections from other encapsulated organisms,
may represent a possible side effect of the medication.
Further research, specifically, larger scale prospective
studies, are needed to better assess the degree of
efficacy and safety of eculizumab for gemcitabineinduced TMA.
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Metformin Associated Lactic Acidosis
Jinyu Zhang, MD, Ravi Sunderkrishnan, MD, Samantha Brackett, MS4, Maham Qureshi, MD,
Keithe Shensky, MD, Rakesh Gulati, MD

INTRODUCTION

DIFFERENTIAL DIAGNOSIS

Metformin is a first line oral medication for diabetes mellitus
shown to decrease cardiovascular morbidity and mortality.
Though the prevalence of metformin-associated lactic
acidosis (MALA) is low, mortality is high, ranging from
25-50%. Therefore, it presents a diagnostic challenge
that is critical to identify, particularly in patients with renal
impairment at baseline. Traditionally patients with creatinine
greater than 1.5 mg/dL have been excluded from using
metformin; however, metformin might be acceptable in
some patients with chronic kidney disease (CKD).

The differential was broad including septic shock, toxin
ingestion, cardiogenic shock, and intracranial abnormality.
Drug toxicity was ruled out as her urine drug screen and
alcohol level were negative. Severe sepsis was ruled out when
cultures (urine, blood, bronchoalveolar lavage) were negative.
CT chest, abdomen, and pelvis did not show any source of
infection. CT head was within normal limits. A transthoracic
echocardiogram did not show significant abnormalities. Given
her elevated anion gap metabolic acidosis with concomitant
osmolar gap, a diagnosis of MALA was made.

CASE PRESENTATION:
A 69 year old female with a past medical history of diabetes
mellitus, hypertension, breast cancer, and no chronic
kidney disease was sent to the hospital by her rehabilitation
facility secondary to her being found unresponsive. This
was in the presence of decreased appetite and impaired
mobility limiting her ability to feed herself in the 2 weeks
prior to hospital admission. Her medications included
metformin, insulin glargine, anastrazole, and hydrochlorothiazide. She had nausea and vomiting the night prior
to admission. Despite her decreased oral intake, she
continued taking her full dose of metformin and insulin
throughout that two week period.
On arrival to the emergency room, her vitals were rectal
temperature 90.6° F, heart rate 66 beats per minute,
blood pressure 60/40 mmHg, respiratory rate 25 breaths
per minute, and oxygen saturation 88% on room air. Her
Glasgow Coma Scale was 2 with physical exam findings
significant for limited withdrawal to noxious stimuli. Her
initial labs were significant for bicarbonate of 2 mEq/L
(normal range 24-32 mEq/L), potassium of 6.7 mEq/L
(normal range 3.5-5.0 mEq/L), blood urea nitrogen of 110
mg/dL (normal range 7-26 mg/dL), creatinine of 9.7 mg/
dL (normal range 0.7-1.4mg/dL) with a baseline of 0.7 mg/
dL 2 months ago, and lactate of 26 mmol/L (normal range
0.5-2.2 mmol/L). A venous blood gas was significant for a
pH of 6.65. Plasma metformin level was not available.

OUTCOME AND FOLLOW UP
Patient was intubated and admitted to the medical
intensive care unit. She was empirically started on broadspectrum antibiotics, stress dose steroids, intravenous
fluids, and vasopressors for presumed septic shock. Given
her low bicarbonate level, a bicarbonate drip was started,
and nephrology was consulted for acute renal failure
and metabolic acidosis management. The nephrology
team initiated her on continuous veno-venous hemofiltration (CVVH) therapy. She had 3 days of CVVH, after
which she was transitioned to intermittent hemodialysis.
Patient’s urine output gradually improved throughout her
hospital stay. Upon discharge, she was alert, oriented, and
conversing appropriately.

DISCUSSION
Metformin is renally cleared and therefore accumulates in
states of decreased creatinine clearance. It also inhibits
mitochondrial electron transport, thereby increasing
anaerobic metabolism and lactate production.1 It has
been proposed that in acute kidney injury, metformin
levels accumulate, contributing to worsening lactic
acidosis, which further compounds nausea and vomiting,
and thereby reducing renal perfusion.2 The incidence of
MALA is thought to be 1-5 cases per 100,000 patient years
but can be as high as 30 cases per 100,000 patient years.3
Mortality ranges from 25-50%.4
The 5 characteristics highly suggestive of MALA are: severe
acidemia (pH < 7.1) with an anion gap greater than 20
mEq/L (normal anion gap ≤ 12 mEq/L), very low serum
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bicarbonate (7 +/- 4 mEq/L), markedly elevated lactic acid
(12.4 +/- 8 mmol/L), history of metformin ingestion, and
history of renal insufficiency.1,5 With infectious and other
drug toxicities ruled out in this patient, MALA was the most
likely cause of her lactic acidosis as the patient met all 5
aforementioned points. We propose that this patient, in
the presence of decreased oral intake in the weeks prior
to her presentation, developed acute kidney injury, which
decreased her ability to clear metformin. Consequently,
she started developing lactic acidosis, which likely
worsened any nausea or vomiting, further exacerbating
her acute renal failure leading to anuria.
Given the lack of randomized control trials in the study of
MALA, much of the existing literature on MALA are case
series, retrospective studies, and observations. The goal
in the acute management of MALA is to provide airway,
breathing, and circulatory support and to correct the
underlying acidosis with possible intravenous bicarbonate
and/or renal replacement therapy.6
A retrospective analysis study compared cases of severe
acidosis with pH < 7.0 secondary to MALA and lactic
acidoses of other origins. Despite the pH being lower in the
former group, the mortality was 100% in the latter group as
compared to 50% in the former. This shows that despite a
greater degree of acidosis and renal failure in MALA patients,
early recognition and aggressive medical therapy including
renal replacement therapy improves the survival.7
A recently published retrospective study looked at the
incidence of MALA in those with and without impaired
renal function. The 77,601 identified patients were divided
into different groups based on glomerular filtration rate
(GFR): normal, mildly reduced, moderately reduced, or
severely reduced. They found an incidence of 10.37 per
100,000 patient years. What is more significant is that they
did not find a significant difference in the development of
MALA among the 4 groups.8 This calls for more awareness
amongst general internists such that impending signs
of MALA should be recognized earlier. A recent review
article suggests that given the mild association between
metformin and lactic acidosis, metformin can be used in
those with impaired renal function but should be dosed by
GFR secondary to metformin’s varied benefits.9
Prognosis of MALA is more favorable than other etiologies
of lactic acidosis.1,10 This may be secondary to the absence
of a critical underlying condition causing lactic acidosis
such as severe ischemia. Rather the lactic acidosis is a result
of toxic drug accumulation, which can be successfully

removed by renal replacement therapy.10 Furthermore,
though our patient did not have any CKD at baseline, she
should have been counseled on stopping her metformin
during periods of poor appetite or dehydration. Physicians
need to be comfortable and knowledgeable with using
metformin alongside medications that interfere with renal
hemodynamic regulation such as angiotensin-convertingenzyme inhibitors, aldosterone receptor blockers, and
nonsteroidal anti-inflammatory drugs.3

KEY POINTS
Metformin is currently a first-line agent in the management
of diabetes. Though it can cause metformin-associated
lactic acidosis, the prevalence is relatively low. High clinical
suspicion is, however, important. In those taking metformin
and presenting with lactate greater than 15 mmol/L and pH
less than 7, MALA must be strongly considered. To prevent
MALA, patients on metformin should be counseled on its use
in states of potential kidney injury such as volume depletion
as was the case in our patient. Overall, patients who have
MALA should receive aggressive resuscitation methods
including fluid repletion, airway protection, vasopressors,
intravenous bicarbonate, and/or renal replacement therapy
depending on the severity of the acidosis.
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Nephrotic Syndrome: Is HIV Associated
Nephropathy on Your Differential?
Jad Al Danaf, MD, Jeffrey Marbach, MD, Sharon Li, MS4, Emily Stewart, MD

CASE DESCRIPTION
A 30-year old African American female with no significant
past medical history initially presented to our emergency
department with three days of sore throat, dysphagia,
fever, fatigue, nausea and vomiting. She denied ear pain,
rhinorrhea, shortness of breath or any sick contacts. Her
social history was negative for tobacco, alcohol and illicit
drug use. She works as a security officer, lives with her
family and is sexually active only with her husband. On
initial examination she was febrile to 101.9° F, with a heart
rate of 100 beats per minute, blood pressure of 143/99
mmHg, respiratory rate of 18 breaths per minute and an
oxygen saturation of 99% on room air. Her only pertinent
physical examination findings were a mildly erythematous
oropharynx without exudates, mildly swollen uvula and
right tonsil, bilateral tender swollen sub-mandibular
lymph nodes and reduced breath sounds on auscultation
of the right lower lung base.She was routinely tested for
HIV, ruled out for group A strep, and discharged home
with the diagnosis of viral pharyngitis on supportive care.
Following the identification of a presumptive positive
rapid HIV screening test with evidence of HIV-1 p24
antigen and a reactive HIV-1 antibody on the multispot
HIV 1 / 2 antibody test she was called to return to the ED
for counseling regarding a positive HIV test. She reported
continuation of her prior symptoms with worsening
dysphagia, as well as new complaints of bilateral lower
extremity edema to the knees. Initial laboratory testing
revealed an elevated serum creatinine (Cr) of 2.2mg/dL
(0.7-1.3 mg/dL) up from <1.0mg/dL one-year prior, with
an estimated Creatinine clearance (CrCl) of 43.4 ml/min
using the modified Cockcroft-Gault equation. She was
admitted for further workup. A trial of IV fluid hydration
overnight worsened her symptoms and additional labs
demonstrated hypoalbuminemia, 4+ proteinuria with
1+ blood, and a urine protein/creatinine ratio of 17mg/
mg (<0.2 mg/mg), consistent with nephrotic syndrome.
Her CD4 count was 115 cells/mm3 (500-1500 cells/
mm3) with an HIV viral load of 117,148 copies/ml.
Based off negative labs for syphilis, hepatitis panel, ANA,
complement C3/C4, and diabetes, findings were felt to
be consistent with HIV Associated Nephropathy (HIVAN).
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The patient underwent renal biopsy to confirm the diagnosis
and was started on abacavir, darunavir, dolutegravir,
lamivudine and ritonavir. Pathology results were consistent
with HIVAN with tubulointerstitial nephritis and collapsing
glomerulonephropathy and electron microscopy
showed diffuse epithelial cell injury with effacement of
foot processes and segmental collapse of glomerular
capillary loops. Her serum Cr peaked at 2.78 on day 7 of
her admission. Her serum Cr and urea-nitrogen steadily
improved after just one week of HAART therapy leading
to a 42% reduction in serum Cr (Figure 1). Additionally,
due to her un-resolving dysphagia the patient underwent
esophagogastroduodenoscopy, which was unremarkable.
However, she subsequently had esophageal manometry,
which was consistent with diffuse esophageal spasm for
which she was started on diltiazem.

DISCUSSION
HIV-associated nephropathy (HIVAN) is an aggressive form
of collapsing focal segmental glomerulosclerosis and
tubulointerstitial lesions that is observed predominantly
in African Americans. The first descriptions of this
disease manifestation were among African-American
and Haitian immigrants with advanced HIV illness, which
serve to highlight the racial disparity and genetic susceptibility to HIVAN.1 The era of highly active antiretroviral
therapy (HAART) has reduced the incidence of HIVAN;
however, HIVAN remains the 3rd leading cause of end
stage renal disease (ESRD) among blacks between the
ages of 20-64 years old, with an estimated 90% of
patients with ESRD attributed to HIVAN being of AfricanAmerican descent.2 Although incompletely understood
it has been postulated that the pathogenesis of HIVAN
involves several factors, including direct HIV infection of
glomerular and tubular epithelial cells and upregulation
of host cellular pathways involved in apoptosis and
cell cycle arrest. 3-5 As previously mentioned, current
therapy involves initiation of HAART, along with renal
replacement therapy and renin-angiotensin system
inhibitors as warranted.

Figure 1. Trend of serum
creatinine (Cr) (normal
range: 0.7-1.3 mg/dL)
and serum urea-nitrogen
(mg/dL) (normal range:
8-20 mg/dL) since
presentation to the ED
(day 0) across time (days).

Ultimately, HIV prevention remains the best approach to
impact the epidemiology of HIVAN. In this case report, it
was not clear for exactly how long the patient had HIV,
however if it was a recent transmission it would have
been a rare case of HIVAN in the setting of sub-acute HIV
infection. Additional high quality studies and randomized
clinical trials are needed to establish treatment beyond
HAART for HIVAN, taking into account the recent
progress in the understanding of the pathogenesis of
HIVAN in the existing body of literature. Furthermore, it
is still not clear which of the combination antiretroviral
therapies (cART) available are effective in treating HIVAN
and to what extent they are achieving survival and
morbidity reductions.

REFERENCES
1. Wyatt CM, Klotman PE, D’Agati VD. 2008. HIV-associated
nephropathy: clinical presentation, pathology, and epidemiology
in the era of antiretroviral therapy. Semin. Nephrol. 28(6):513–22
2. United States Renal Data System. 2010. USRDS 2010 Annual Data
Report: Atlas of Chronic Kidney Disease and End-Stage Renal
Disease in the United States. http://www.usrds.org/adr.htm
3. Rosenstiel P, Gharavi A, D’Agati V, et al. 2009. Transgenic and
infectious animal models of HIV associated nephropathy. J. Am.
Soc. Nephrol. 20(11):2296–304
4. Bruggeman LA, Ross MD, Tanji N, et al. Renal epithelium is a
previously unrecognized site of HIV-1 infection. J Am SocNephrol
2000; 11:2079.
5. Ross MJ, Bruggeman LA, Wilson PD, Klotman PE.Microcyst
formation and HIVB-1 gene expression occur in multiple nephron
segments in HIV-associated nephropathy. J Am SocNephrol 2001;
12:2645.

SUMMARY
This case serves as an example of an uncommon
yet dangerous complication of HIV. In the setting of
nephrotic syndrome, screening for HIV infection and
ruling out HIVAN in HIV-infected individuals is essential.
HIVAN may be the first manifestation of HIV-1 infection
in an otherwise asymptomatic patient and preservation
of renal function in African Americans with chronic
kidney disease and HIV is dependent upon its prompt
recognition and early treatment. Early recognition
and treatment of HIVAN has the potential to delay the
onset of ESRD and improve mortality associated with
complications of HIV.
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Persistent Fever and Pancytopenia:
Lupus Flare vs Macrophage Activation Syndrome
Amy McGhee, MD

INTRODUCTION
Macrophage activation syndrome (MAS), first named in
1993, is a subcategory of hemophagocytic lymphohistiocytosis (HLH), characterized by prolonged fever, hepatosplenomegaly, pancytopenia, liver dysfunction, and most
notably hyperferritinemia. MAS, in particular, is the term
used to describe secondary HLH, or HLH caused by
rheumatologic conditions. Secondary HLH can also be
associated with other systemic autoimmune diseases,
underlying malignancy, infection, or medications and can
be a life-threatening complication. MAS is characterized
by unwarranted proliferation and stimulation of T cells
and benign macrophages leading to an excessive
inflammatory state with hypersecretion of cytokines.
This, in turn, leads to phagocytosis of normal blood cells
and injury to the organs containing these macrophages
(liver, spleen, bone marrow, lymph nodes). With regard
to rheumatologic conditions, MAS is most often seen
associated with juvenile idiopathic arthritis (incidence of
7-13%) while it is much less commonly seen in systemic
lupus erythematosus (SLE) with an incidence of 0.9-4.6%.
The etiology is unknown, although there are hypotheses.

CASE PRESENTATION
A 53 year old female with SLE complicated by lupus
nephritis and lupus anticoagulant initially presented with
a syncopal episode. While walking out of the rheumatologist office, she felt faint and had an assisted fall to
the floor with transient loss of consciousness. The patient
reported approximately 1-2 months of decreased oral
intake, weight loss, daily fevers to 102-103°F, lightheadedness, dry cough, and 1 week of rash on her upper
chest. During this time, her rheumatologist adjusted her
SLE medications, attributing her symptoms to a SLE flare.
Work up during this admission (labs listed in Table 1) ruled
out sepsis as a source of fever. It was determined that her
symptoms and lab abnormalities were likely secondary to a
lupus flare given her fever, rash, constitutional symptoms,
and pancytopenia in the setting of SLE that was difficult
to control. Early macrophage activation syndrome (MAS)
was also on the differential given the elevated ferritin
level. Her symptoms improved with pulse dose steroids
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and resuming mycophenolate mofetil for immunosuppression. The plan was to change this to cyclosporine as
an outpatient to prevent MAS.
Before switching to cyclosporine however, the patient
was readmitted for recurrent fevers, fatigue, diarrhea, and
worsening lab abnormalities. On admission, her physical
exam was significant for fever to 102.4°F, tachycardia,
and dry mucus membranes. Labs are shown in Table
2. The most remarkable finding was a ferritin of 11,741
which was a significant increase from 4,542 during her
last admission. The patient underwent a bone marrow
biopsy, which demonstrated increased macrophages with
hemophagocytic activity, confirming a diagnosis of MAS.

DIFFERENTIAL DIAGNOSIS
In an SLE patient with recent flare 4 months ago, a
recurrent lupus flare was highest on the differential as the
patient reported joint pain, skin rash, fevers, weight loss,
and fatigue. Infection is also high on the differential for
a patient on chronic immunosuppression who presents
with fever. An infectious workup was undertaken
including a Right upper quadrant ultrasound, chest CT,
blood cultures, urine cultures, respiratory viral panel,
and transthoracic echo, all of which were negative for
infection. Anti-dsDNA antibodies were unexpectedly
normal and complement levels were unremarkable
which made a SLE flare less likely.
During the initial admission, the hyperferritinemia, an
acute phase reactant, was thought to be elevated in
the setting of a lupus flare or infection. However, the
dramatic increase to 11,741 upon readmission raised
suspicion for MAS. Multiple case reports have described
this diagnostic difficulty in distinguishing between MAS
and a SLE flare. It has been reported that elevation of
ferritin (greater than or equal to 500ug/L) and LDH can
help differentiate as this represents activation of the
mononuclear phagocyte system. Hyperferritinemia has
a sensitivity and specificity of almost 100% for distinguishing between a SLE flare and MAS. Lastly, a bone
marrow biopsy is usually diagnostic for MAS if there is
still uncertainty.

Table 1. Labs for first admission.
Lab

Result

Lab

Result

WBC (B/L)

1.2

L

AST (U/L)

71

Hemoglobin (g/dL)

7.4

L

ALT (U/L)

23

Platelets (B/L)

178

Alk phosphatase (U/L)

35

Sodium (mmol/L)

137

Lactate (mmol/L)

1.1

Potassium (mmol/L)

4.4

Iron (mcg/dL)

44

Chloride (mmol/L)

103

Iron Binding Capacity (mcg/
dL)

179

Bicarbonate (mmol/L)

22

Iron Saturation (%)

25

BUN (mg/dL)

21

Ferritin (ng/mL)

4542

H

Creatinine (mg/dL)

0.9

ESR (mm/hr)

114

H

Glucose (mg/dL)

127

CRP (mg/dL)

1.50

H

PTT (sec)

42

C3 complement (mg/dL)

79

L

PT (sec)

10.1

C4 complement (mg/dL)

12

INR

0.93

Anti-dsDNA Ab (IU)

25

Total Protein (g/dL)

5.1

L

Haptoglobin (mg/dL)

295

H

Albumin (g/dL)

2.8

L

LDH (IU/L)

396

H

Total bilirubin (mg/dL)

0.2

Vitamin B12 (pg/mL)

433

Direct bilirubin (mg/dL)

<0.2

Folate (ng/mL)

>20

Urinalysis

2+ protein

L

H

H

L

Trace blood
1 RBC 4 WBC

Table 2. Labs upon second admission.
Lab

Result

Lab

Result

WBC (B/L)

0.9

L

AST (U/L)

128

H

Hemoglobin (g/dL)

8.5

L

ALT (U/L)

49

H

Platelets (B/L)

72

L

Alk phosphatase (U/L)

41

Total Protein (g/dL)

5.6

L

Ferritin (ng/mL)

11741 H

Albumin (g/dL)

3.1

L

LDH (IU/L)

1135

Total bilirubin (mg/dL)

0.6

H
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OUTCOME AND FOLLOW-UP
Once the diagnosis of MAS was confirmed, the patient
was treated with cyclosporine, anakinra (IL-1 receptor
blocker), and high dose steroids. These were uptitrated
until the ferritin, leukopenia, and liver function tests
began to improve. Interestingly, in the work-up of the
patient’s pancytopenia, her EBV studies showed a positive
VCA IgG and ENA IgG so the patient was also treated
with IVIG in case an EBV infection was contributing
to the MAS. The patient was discharged home after a
month-long hospitalization. In the next nine months,
her medications were all gradually tapered and she had
a concordant improvement in ferritin, blood counts, and
symptoms.

DISCUSSION
There remain many uncertainties surrounding MAS
including its etiology, treatment, and prognosis. In
one case study of a patient with SLE and MAS, the
patient tested positive for numerous antibodies (ANA,
anti-dsDNA, anti-Sm, anti-RNP, anti-Ro, and peripheral
ANCA antibodies). It was hypothesized that the
overwhelming amount of autoantibodies and immune
complexes bound to normal blood cells trigger
phagocytosis of those cells. It is possible that the quantity
of these autoantibodies and the increased complement
activity during a SLE flare can trigger MAS.
Once the diagnosis of MAS is made, it is important to
initiate therapy quickly as it can be a life-threatening
illness. The cornerstone of therapy is high dose steroids.
Multiple case reports also discuss the importance of
immunosuppressant medications, such as cyclosporine
A and cyclophosphamide in patients who do not respond
to steroids, such as the patient in this report. One study,
in particular, demonstrated 54% of patients with MAS
from systemic autoimmune disease who received only
high dose steroids were resistant to this treatment and
the majority of patients who were treated with both
steroids and immunosuppression had good treatment
response. Another case report demonstrated the fairly
rapid improvement in labs and clinical condition of a
young man who was treated with cyclosporine when
he did not respond to steroids. IVIG is another treatment
option which is especially useful in patients who are
suspected to have an underlying viral infection. Further,
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the next line of treatment if both steroids and immunosuppression are not effective is biologic agents, such
as anakinra and rituximab. Anakinra is an IL-1 receptor
blocker that has been used effectively in patients
with MAS secondary to SLE which did not respond to
steroids, IVIG, and cyclosporine. There is also evidence
that rituximab is effective in treating resistant MAS. The
patient in this case study did not respond appropriately
to pulse dose steroids, cyclosporine, or IVIG, so she was
started on anakinra and did well after a few weeks on
this regimen.
Further, prognosis is another area of uncertainty in MAS.
There have been no prognostic indicators established
yet but there is evidence suggesting the level of certain
cytokines can be associated with a worse prognosis and
that ferritin levels may help predict outcome. Multiple
studies have found no correlation between ferritin
levels and the severity of disease or outcome; however,
serial ferritin levels may shed more light on prognosis.
The patient in this case report had a ferritin of 4500
on initial admission, which increased to 11,000 on her
subsequent admission indicating lack of response to
therapy. Once anakinra was added and titrated, her
symptoms improved and her ferritin slowly decreased
over the course of weeks. She was safely discharged
home with close follow up.

KEY POINTS
MAS is a potentially life-threatening complication of
rheumatologic diseases, characterized by excessive
activation of benign macrophages which lead to
the phagocytosis of normal blood cells and injury to
surrounding tissues. Common clinical manifestations
include fever, pancytopenia, liver dysfunction, hepatosplenomegaly, and hyperferritinemia. Diagnosis can be
difficult as the signs and symptoms of MAS can mimic
an infection or SLE flare. However, hyperferritinemia and
elevated LDH are characteristic of MAS and may help
distinguish and guide treatment decisions. If uncertainty
remains, a bone marrow biopsy can usually establish
the diagnosis. The best treatment options at this point
include high dose steroids, immunosuppression, IVIG,
and biologics depending on the patient’s laboratory and
clinical response.

REFERENCES
1. Atteritano M, David A, Bagnato G, Beninati C, Frisina A, Iaria C,
Bagnato G, Cascio A. Haemophagycytic syndrome in rheumatic
patients. A systematic review. European Review for Medical and
Pharmacological Sciences. 2012; 16: 1414-1424.
2. Bakshi J, Hassan S, D’Cruz D, Chan C. Rituximab therapy
in refractory macrophage activation syndrome secondary to
systemic lupus erythematosus. Lupus. 2013; 22: 1544-1546.
3. Dubuc CAE, Ecenarro MU, Villalba CM, Cåceres VA, Rubio IH,
Otano JB. Hemophagocytic syndrome as the initial manifestation
of systemic lupus erythematosus. Reumatologìa Clìnica. 2014;
10(5): 321-324

5. Kim JM,Kwok SK, Ju JH, Park KS, Park GS, Kim HY, Park SH.
Macrophage activation syndrome resistant to medical therapy in a
patient with systemic lupus erythematosus and its remission with
splenectomy. Rheumatol Int. 2013; 33: 767-771.
6. Maruyama J and Inokuma S. Cytokine profiles of macrophage
activation syndrome associated with rheumatic diseases. The
Journal of Rheumatology. 2010; 37(5): 967-973.
7. Vilaiyuk S, Sirachainan N, Wanitkun S, Pirojsakul K, Vaewpanich
J. Recurrent macrophage activation syndrome as the primary
manifestation in systemic lupus erythematosus and the benefit
of serial ferritin measurements: a case-based review. Clinical
Rheumatology. 2013; 32: 899-904.

4. Jung S. Hemophagocytic syndrome diagnosed by liver biopsy in
a female patient with systemic lupus erythematosus. Journal of
Clinical Rheumatology. 2013; 19(8): 449-451.

Philadelphia Sunset Skyline by Ashish Shah, MD

The Medicine Forum | 25 5

Pulmonary Mucormycosis in a patient with
Acute Myeloid Leukemia
Jonathan Pan, MD, Margaret Kasner, MD, Sheel Patel, MD, Gretchen Diemer, MD

INTRODUCTION

OUTCOME AND FOLLOW UP

Mucormycosis is a rare fungal infection that is common
amongst uncontrolled diabetics and immunocompromised patients. The most common clinical
presentation is rhino-orbital-cerebral infection, which
typically affects diabetics with ketoacidosis. 1 Less
commonly, pulmonary mucormycosis can occur in
patients with hematologic malignancy, solid organ
transplant and patients taking steroids or deferoxamine.1
The following report describes a 25-year-old male
with Acute Myeloid Leukemia (AML) who developed a
pulmonary mucormycosis infection. With a mortality
rate of about 87%, this case represents a favorable
outcome for a rare and often lethal diagnosis.

A CT-guided biopsy of the pulmonary consolidation
was performed. Pathology revealed granulomatous
inflammation with necrosis and silver stain showed
sparsely septate hyphae consistent with mucormycosis.
High-dose ambisome was initiated and the patient
began to demonstrate signs of clinical improvement.
He was discharged on a six-week course of intravenous
ambisome. Follow-up imaging showed improvement of
the consolidations and the patient was switched to oral
posaconazle for six additional weeks.

CASE DESCRIPTION
A 25-year-old male with no past medical history presented
to the hospital after two weeks of fatigue, shortness of
breath and epistaxis. Lab work revealed leukocytosis
with 43% blasts, anemia and thrombocytopenia. A bone
marrow biopsy confirmed the diagnosis of AML. After
admission, the patient developed persistent fevers and
CT scan demonstrated ground-glass opacities in bilateral
lung fields. Blood and sputum cultures, respiratory
viral panel and acid fast studies were negative and the
patient was started on antifungals and broad spectrum
antibiotics. Bronchoscopy with bronchoalveolar
lavage did not reveal an infectious source. The patient
underwent induction chemotherapy with idarubicin and
cytarabine, which was initially well tolerated. However,
he soon developed neutropenic fever, hypoxia, and a
non-productive cough. The treatment was broadened
from vancomycin, zosyn and micafungin to meropenem
and ambisome. Cultures remained negative during this
time and subsequent imaging revealed right-middle and
left-upper lobe consolidations with a central lucency.
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DISCUSSION
Mucormycosis is a rare opportunistic fungal infection
caused by fungi in the mucorales order, including
mucor, rhizopus and absidia.3 These fungi are ubiquitous
in nature, commonly found in soil and decaying matter
and released via airborne spores. Histologically, hyphae
are seen in broad, irregular branches with few septations,
as opposed to aspergilli, which have acute branching
angles and many septations. Comprising a unique
category of angioinvasive molds, tissue infarction is a
hallmark of the disease process.4 Risk factors include
diabetes, hematologic malignancy, solid organ or stem
cell transplant, immunocompromised state, iron overload
and treatment with deferoxamine.5 While incidence is
difficult to estimate due to mucormycosis not being a
reportable disease, it is estimated that approximately 500
cases occur in the US each year.6 As rhino-orbital-cerebral
infection is the most common clinical manifestation in
diabetics, pulmonary mucormycosis is more commonly
seen with hematologic malignancy, transplant patients
and steroid or deferoxamine use. It is caused by direct
inhalation of spores into bronchioles and alveoli, which
presents as a rapidly progressing pneumonia with or
without hemoptysis.7 Clinical presentation is similar to
that of other angioinvasive molds such as aspergillus or
fusarium, and diagnosis is therefore obtained by culture
and pathology. Imaging can show non-specific findings
such as focal consolidation, nodules, masses, or pleural
effusions. A halo sign on CT scan, which shows ground

glass attenuation surrounding a nodule, is characteristic
of pulmonary aspergillus. A reverse halo-sign, on the
other hand, shows focal ground glass attenuation within
a ring of consolidation and is more commonly seen with
mucormycosis. As cultures are typically negative, tissue
diagnosis is often pursued. A biopsy with silver stain will
typically reveal broad, irregular, branching hyphae.
In cases where pulmonary mucormycosis is localized to a
single lobe, surgical excision can be performed. However,
first line treatment for pulmonary mucormycosis remains
high-dose, intravenous amphotericin B. Liposomal
amphotericin is preferred due to improved efficacy and
safety, although renal function and electrolytes must
nonetheless be carefully monitored. Treatment should
be initiated for several weeks until the patient clinically
improves. At this time, amphotericin may be switched to
oral posaconzale , which is often continued for several
months until attainment of both clinical and radiographic
resolution.
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KEY POINTS
This case represents a rare and difficult diagnosis of
pulmonary mucormycosis in a patient with hematologic
malignancy. While a rapidly progressive disease with a
high mortality rate, the patient in this case experienced a
favorable outcome. Diagnosis was made only after invasive
testing and successful treatment was achieved with an
extended course of high dose intravenous ambisome.
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A Retinal Tear Induced By Pazopanib Therapy:
A Case Report
Raza Hasan, MD

INTRODUCTION
The management of renal cell carcinoma has undergone
major transformation in recent years. With the onset of
innovative surgical treatments and systemic medications
– there has been an overall decrease in mortality.1 The
systemic medications that target the vascular endothelial
growth factor (VEGF) protein have created the most
potent effects, especially when treating metastatic renal
cell carcinoma. These prove to be important treatments
since renal cell carcinoma has become the seventh
most common cancer in men, with a general prevalence
of 2-3%.2 With more advancement in knowledge about
renal cell carcinoma, research has shown the utility of
pazopanib (Votrient), a specific tyrosine kinase inhibitor,
targeting multiple receptors; its action is primarily to
block angiogenesis and tumor growth, such as VEGFR-1,
VEGFR-2, VEGFR-3, PDGFR-A, PDGFR-B, FGFR-1, and
FGFR-3. 3 Targeting these specific receptors helps
pazopanib to achieve an overall clinical benefit rate of
greater than 90%, creating long-lasting disease control
for patients 4

Additional therapeutic options were discussed with
the patient, such as high-dose interleukin-2 infusion
to achieve durable remission and then potentially start
targeted therapy when needed. At the time when she
was diagnosed with metastatic disease, the patient
was in optimal health and was an excellent candidate
for high-dose interleukin-2 treatment because she only
had pulmonary nodules, without evidence of metastatic
disease elsewhere in her body. She was agreeable and
finished three cycles of high-dose interleukin-2 treatment
along with Stereotactic Body Radiation Therapy. The
patient was finally started on targeted therapy with a
multi-tyrosine kinase inhibitor in June of 2013. Pazopanib
400mg daily was started and titrated up to 600mg
daily, which is considered optimal therapy. However,
this patient began to have significant diarrhea without
relief from Lomotil and other antidiarrheal medication
regimens. Her dose was decreased to 400mg daily
which resulted in a decreased amount of diarrhea - one
to two times a day which was tolerable. Additionally, a
few months after the onset of pazopanib treatment, the
patient began having blurry vision, a symptom which
was very worrisome.

CASE PRESENTATION
A 63 year old Caucasian female with a past medical
history of migraine headaches, dyslipidemia and
depression was diagnosed with clear cell type Renal
Cell Cancer, in late 2004. She underwent a laparoscopic
nephrectomy in 2005 and a kidney mass measuring 9 x
7 x 4 cm was removed, revealing T2 disease with Furman
Grade 2 disease. The patient was followed for years and
had a CT scan of her Chest in June of 2012 - where
multiple bilateral pulmonary nodules were identified, the
largest nodule was a 1.5 x 1.2 cm nodule at the right
middle lobe. CT-guided biopsy was attempted, however
was not diagnostic. Therefore, the patient underwent a
right upper lobe wedge resection in October of 2012,
which confirmed metastatic renal cell cancer to the
lung. A PET/CT scan was also performed, and ruled out
any evidence of abdominal or bone metastatic disease.
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DIFFERENTIAL DIAGNOSIS
The patient’s blurry vision was the main symptom of
concern – her vision had been gradually worsening
since the start of pazopanib therapy. Therefore, it was
suspected that the systemic therapy was a plausible
causal agent of the blurry vision. Upon visiting the ophthalmologist, she was diagnosed with Rhegmatogenous
Retinal Tear OD. Her past ocular history was negative
for any prior chronic diseases. On exam, the patient had
retinal detachment, superotemporal (horseshoe) tear.
Furthermore, the patient's left eye exam was remarkable
for nuclear sclerosis. It was likely determined that the
pazopanib caused a tear in the retina, thus further
leading to detachment

OUTCOME AND FOLLOW-UP
To treat the pazopanib induced retinopathy, the patient
had a pneumatic retinopexy performed on August
19, 2014 and was started on Maxitrol 0.1% 1 drop OD,
four times a day. Post operatively, she had decreased
complaints of blurry vision. However, because of this
adverse event along with intractable diarrhea, the
patient was switched from pazopanib to Sutent 37.5mg
daily. The Patient is currently doing well – the blurry
vision has not worsened and is slowly improving after
stopping pazopanib.

DISCUSSION
The usage of pazopanib is a common treatment in
metastatic renal cell carcinoma. A multitude of studies
have shown that “pazopanib demonstrated significant
improvements in progression-free survival and response
rate compared with placebo in patients with advanced
or metastatic RCC.”7 Furthermore during these studies,
there were no reports of patients developing other
systemic abnormalities; the medication demonstrated
acceptable safety and tolerability. However, as
pazopanib is an oral angiogenesis inhibitor targeting
specifically VEGF receptor, it is important to evaluate
other locations in the body that might be affected
secondary to inhibiting VEGF receptors.
A recent study was published evaluating the ocular
effects of Sorafenib – as it was shown that many cancer
signaling molecules, such as VEGF, were also expressed
in ocular tissue.5,6 Sorafenib and Pazopanib have similar
pathways, both specifically targeting VEGF proteins and
thus both affecting the ocular tissue. Furthermore, there
have been studies analyzing the effect of pazopanib in
mice retinal tissues – specifically studying pazopanib’s
effect on inhibiting choroidal neovascularization. It was
shown that pazopanib primarily down-regulates the
VEGF release in the retina and impairs VEGF-induced
signaling and chemotaxis.8 Thus, a clear link is illustrated
between pazopanib and its effect on retinal tissue.
Furthermore, studies have shown that if pazopanib is
“orally administered, [it] has good bioavailability to the
retina/choroid” further giving proof to its profound
effect on the retina and likely impact on treating ocular
abnormalities, such as choroidal neovascularization by
inhibiting angiogenesis.9,10

However, analysis of the link between pazopanib and
retinal tears is important to be determined – in order
to understand the findings in this case. Case reports of
retinal effects from Sorafenib have been reported, likely
secondary to a similarity between the VEGF receptors
targeted in systemic RCC and in ocular tissue; similarly
a comparison can be drawn between pazopanib and
its effects on ocular tissues. With pazopanib’s large
bioavailability in ocular tissues, and its direct effect on
VEGF receptors – there can be a correlation made
between pazopanib and retinal tears developing after
initiating chemotherapy. Retinal tears occur when
the retinal tissue begins to peel away from supporting
tissue. Rhegmatogenous retinal detachment, the type
of retinal attachment the patient in above case had,
occurs primarily when a small retinal tear allows for fluid
to pass from vitreous space into subretinal space where
the retinal pigment epithelium (RPE) is located. Studies
have illustrated that these tears are often preceded
by anti-VEGF therapy, stating that an “increased risk
of developing a retinal pigment epithelium tear after
anti-VEGF therapy” is common in many patients.11 This
occurs because following the administration of anti-VEGF
therapy, there is rapid involution and contraction of the
neovascular tissue that is attached to the undersurface of
the retinal pigment epithelium. Those forces will cause a
contractile force of the RPE forcing a tear on the retinal
tissue.12 Given the pathophysiology of retinal tears and
its relationship with anti-VEGF therapy – it is highly
probable that the repeated administration of pazopanib
in therapeutic doses for RCC can lead to strain of the
retinal pigment epithelium, inducing a tear and further
progressing onto a rhegmatogenous retinal detachment.

KEY POINTS
This case illustrates a risk with using VEGF inhibitors,
such as pazopanib, due to the possibility of retinal
damage causing tears leading to detachment. As in our
case, there is an increased amount of anti-VEGF being
used in renal cell carcinoma cases at therapeutic doses.
With the increased usage, guidelines may be required
for annual ophthalmology screening to monitor for
retinal abnormalities. Furthermore, follow up will be
required to determine if discontinuing the pazopanib
and starting Sutent helped deter further ocular
abnormalities. Overall, it should be recommended to
discontinue pazopanib if any blurry vision or vision
changes are noted.
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Rising Prevalence of Pneumocystis jirovecii
Pneumonia Amongst the Non-HIV
Immunosuppressed
Zachary Jones, MD and Anusha Ganesh, MD

Figure 1. Cross Section CT scan with
ground glass opacities, severe interlobar
septal thickening likely related to interstitial
pneumonia and stable postoperative
changes following left pneumonectomy
from day 1 of hospitalization.

Figure 2. Coronal Cut of CT scan demonstrating
severe interstitial pneumonia cut from day 9 of
hospitalization.

INTRODUCTION
Fungal Pneumonia caused by Pnemocystis Jirovecci
(PCP) has long been associated with morbidity and
mortality in HIV-positive patients. With the widespread
use of high dose corticosteroids and biologic therapies,
the prevalence of PCP infection in the non-HIV immunosuppressed population has increased significantly. A lack
of formalized prophylaxis guidelines in these specific
populations has lead to increasing rates of preventable
infection and death.

CASE PRESENTATION
The patient is a 63-year-old man, admitted to the
hospital for persistent shortness of breath following
a seven-day course of Levofloxacin taken as an
outpatient. Two months prior, the patient was found by
his hematologist to have a hemoglobin level of 5.5g/
dL, and was diagnosed with autoimmune hemolytic
anemia. He was started on a 12 week Prednisone taper
following an initial blood transfusion. Three weeks prior
to admission, the patient began to develop shortness
of breath worse with ambulation, a non-productive
cough, and he denied fevers. At time of admission, the
patient was taking Prednisone 40mg daily.

Figure 3. Sagittal cut from CT scan
demonstrating interstitial pneumonia
from day 9 of hospitalization.

The patient’s past medical history was significant for
Hodgkin’s Lymphoma in 2001 treated with Adriamycin,
Bleomycin, Vinblastine and Dacarbazine (ABVD) and
radiation therapy, with recurrence in the nasopharanx
and lung requiring further ABVD cycles and left
pneumonectomy in 2005. Patient also had renal cell
carcinoma requiring nephrectomy in 2007. Social
history was significant for a 5-year pack history of
cigarette smoking. Family history was significant for
myocardial infarction in his father at age 69.
Vital signs at presentation were temperature of 99.4 F,
blood pressure of 157/70, pulse of 105 beats per minute
and oxygen saturation of 90% on room air. Pertinent
positive physical exam findings were sinus tachycardia
and diffuse wheezing in all right lung fields and lack
of breath sounds on the left. Patient was resting
comfortably and able to answer questions without
distress. On admission, patient had a normal white
blood cell count and a hemoglobin level of 9.8g/dL.
Computed tomography scan of the thorax showed
mild diffuse, nonspecific ground glass opacities.
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DIFFERENTIAL DIAGNOSIS

DISCUSSION

The differential diagnoses for shortness of breath in this
specific patient with previously treated hematologic
malignancy currently on chronic steroids is vast,
including pulmonary infection, Chronic Obstructive
Pulmonary Disease (COPD), or volume overload. Also,
two components of ABVD regimen can cause side
effects producing symptoms of shortness of breath:
Adriamycin can cause cardiomyopathy and subsequent
congestive heart failure, and Bleomycin can cause
pulmonary fibrosis. Further possible diagnoses include
pulmonary embolism and opportunistic infection
given his steroid use.

Pneumocystis pneumonia (PCP) is a life threatening
disease caused by the fungus Pneumocystis jirovecii
previously classified as Pneumocystis carinii. While PCP
is historically associated with HIV and CD4 counts less
than 200/μL, there have been increasing case reports
in HIV negative patients treated with high dose steroids,
Methotrexate, Tacrolimus, Infliximab and Etanercept.1 In
the HIV negative population, PCP has a higher likelihood
of causing fulminant pulmonary disease more likely
requiring mechanical ventilation.2

OUTCOME
The patient was initially started on Moxifloxacin
and given Furosemide intravenously. The patient’s
Ventilation/Perfusion scan was negative for embolism,
echocardiogram revealed no systolic dysfunction,
and HIV antibody, Antinuclear antibodies, perinuclear
anti-neutrophil cytoplasmic antibodies (p-ANCA),
cytoplasmic-ANCA (c-ANCA) and rheumatoid factor
were negative. The patient’s respiratory viral and
sputum culture were also negative. A right heart
catheterization completed on day 6 of hospitalization
revealed pulmonary hypertension. Bronchoscopy
was performed on day 10 due to worsening hypoxia
and worsening radiographic evidence of interstitial
process on antibiotics and diuretics (Figure 1,2,3).
Bronchoalveolar lavage demonstrated presence of
Pneumocystis jirovecii.
T h e p a t i e n t w a s s t a r t e d o n Tr i m e t h o p r i m /
Sulfamethoxazole (Bactrim). On day 15, the patient
required continuous Bilevel Positive Airway Pressure
(BIPAP) for worsening hypoxia and was transferred to
the Intensive Care Unit. The patient was transitioned
to intravenous Bactrim and his Prednisone dose was
increased. On day 23, the patient required intubation
and suffered pulseless electrical activity and return of
spontaneous circulation was not achieved after 20
minutes of cardiopulmonary resuscitation.
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In a study looking at those with Adult T Cell Leukemia
treated with corticosteroids, there was a 16.6% overall
risk of PCP infection without prophylaxis.3 In a small case
series of patients with Giant Cell Arteritis treated with
high dose Prednisone, 85% presented on admission
solely with dyspnea, 43% required mechanical
ventilation, and 29% died. 4 The documented PCP
mortality rate ranges from 51% - 80% in HIV negative
patients.1 In a review of neurology literature, up to
90% of patients were treated with high dose corticosteroids prior to diagnosis with PCP.6 In a Cochrane
review of immunocompromised patients without HIV,
thirteen trials showed a reduction of 85% in incidence
of PCP when prophylaxis was administered.6 Across
multiple specialties, no firm prophylaxis guidelines have
been set. It is generally accepted that any patient on
greater than or equal to Prednisone 20 mg per day for
greater than 4 weeks should be considered for PCP
prophylaxis with Bactrim. There was found to be no
statistically significant difference when comparing once
daily versus three times weekly dosing of Bactrim for
prophylaxis.6
The diagnosis of PCP can be delayed due to nonspecific
radiographic findings and vague symptoms at time of
presentation, as seen with our patient who was not
diagnosed until day 10 of hospitalization. Novel serologic
markers that detect PCP have been described, with
B-1,3 Glucan approaching 100% sensitivity but lacking
specificity with regards to detecting PCP. Another
marker, KL-6, is a glycoprotein elevated in interstitial
pneumonitis caused by PCP, which is elevated in the
HIV population, but has not been shown to reliably
detect the disease in non-HIV patients.2 In the non-HIV
immunosuppressed, the mainstay of diagnosis involves
direct sampling via bronchoalveolar lavage and should
be considered early in hospital stay for any patient at
risk for PCP.

Once a diagnosis is made, PCP treatment is similar
regardless of reason for immunosuppression. Bactrim is
the gold standard of therapy with Dapsone, Atovoquone,
or Pentamidine used when Bactrim cannot be
tolerated.7 Duration of treatment is not well established
in non-HIV patients but should extend to at least 14
days in contrast to the minimum of 21 days for the HIV
positive. In patients with HIV and an A-a gradient greater
than 35 mmHg or a PaO2 less than 70mmHg, corticosteroids should given. In contrast, adjunctive high dose
corticosteroids increased mortality in the non-HIV
immunocompromised and are not recommended.8

KEY POINTS
Pneumocystis pneumonia is a devastating disease of
both HIV and non-HIV patients alike. While there are no
formalized guidelines, any patient on a corticosteroid
dose greater or equal to Prednisone 20 mg per day
for more than 4 weeks should be on prophylaxis. In
doing so, the rates of PCP can be drastically lowered
in these patient populations preventing undue burden
of disease.
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Sinus Histiocytosis: An Uncommon Presentation
of an Uncommon Condition
Allison Greco, MD and Gregory Kane, MD

INTRODUCTION
Rosai–Dorfman Disease (RDD), also known as Sinus
Histiocytosis with Massive Lymphadenopathy (SHML), is
a rare, benign, proliferative disorder of macrophages and
monocytes that was first described by Rosai and Dorfman
in 1969. The vast majority of patients present with painless
bilateral cervical lymphadenopathy during childhood or
young adulthood. The condition is self-limited and rarely
requires medical treatment. Involvement of extranodal
sites such as eyelids, eye sockets, skin and subcutaneous
tissue, gastrointestinal tract, upper airways and central
nervous system have been infrequently described.
Mediastinal involvement is extremely rare, and there are
few cases reported in the literature.
Here, we present a case of a 61-year-old female with
a history of mediastinal sinus histiocytosis with massive
lymphadenopathy.

CASE PRESENTATION:
A 61-year-old female with history of hypercholesterolemia
and vitamin D deficiency was referred to the Pulmonary
clinic for evaluation of an abnormal chest radiograph
which was concerning for a right-sided pleural effusion
(Figure 1). The patient noted two to three weeks of
increasing dyspnea on exertion, chest tenderness, a dry
cough, and decreased exercise tolerance. She denied
fevers, chills, night sweats, and weight loss. She reported
a 10-pack-year smoking history, but denied other
occupational exposures. There was no family history
of pulmonary disease or malignancy. Vital signs were
normal, and physical examination was notable only for
decreased breath sounds in the lower one-third of the
right lung and reproducible sternal tenderness.
Upon further review of her past medical history, the
patient stated that she had similar symptoms several
years ago and was subsequently noted to have an
abnormal mass and lymph nodes near her esophagus
in 2010. She underwent mediastinoscopy with biopsy
of these nodes at that time, which was complicated by
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Figure 1. Plain chest radiograph at time of the patient’s presentation
depicting opacity at the right lung base concerning for pleural
effusion.

esophageal perforation and emergent esophageal stent
placement. She was told pathology at that time was
benign and received limited follow up.
A CT of the thorax from initial presentation in 2010 revealed
an abnormal 10 cm, soft tissue mass in the subcarinal
region (Figure 2A). There was a mild, right-sided pleural
effusion with atelectasis in the right lower lobe. Nineteen
biopsy specimens obtained during mediastinoscopy,
including 19 excisional lymph node biopsies, were
negative for malignancy and demonstrated pathology
consistent with sinus histiocytosis with anthracosis.

Figure 3. A CT of the thorax obtained in 2011 demonstrates interval
removal of the esophageal stent, as well as resolving right lower
love atelectasis and scarring. There is resolution of the subcarinal
lymphadenopathy

Figure 2. A CT scan of the thorax obtained in 2010 depicts a 30.8 x
32.8mm mass concerning for malignancy (A). Biopsies of this mass
obtained via mediastinoscopy revealed histology consistent with
sinus histiocytosis. This procedure was complicated by esophageal
perforation and esophageal stent placement, as pictured here (B)

Follow up imaging obtained after esophageal stent
placement showed atelectasis in the right-lower lobe
(Figure 2B).

Figure 4. A non-contrast CT of the Thorax obtained in 2014
demonstrates resolution of the mediastinal mass as well as stable
right lower lobe scarring without evidence of pleural effusion.
These findings account for the right lower lobe opacity seen on
plain chest radiograph (Fig. 1).

Interestingly, a CT of the thorax from 2011 revealed
complete resolution of the subcarinal mass, with
persistent scarring in the right lower lobe (Figure 3).
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DIFFERENTIAL DIAGNOSIS:
Differential diagnosis for the patient’s radiographic
findings at the time of current presentation included
chylothorax given the patient’s history of mediastinal
instrumentation, malignancy, and persistence of sinus
histiocytosis with lymphadenopathy. Additionally the
presence of chest discomfort and shortness of breath
indicated a possible cardiac etiology including valvular or
ischemic heart disease.

have fever and an elevated erythrocyte sedimentation
rate (ESR). Involvement of extranodal sites such as eyelids,
eye sockets, skin and subcutaneous tissue, have been
described. In the rare reported cases of mediastinal SMHL,
patients may have pleural effusion or develop reactive or
interstitial lung disease.
The presence of SHML can be identified histologically by
the presence of large polyclonal histiocytes with abundant
eosinophilic cytoplasm and infrequent mitoses. They
generally demonstrate the expression of the S-100 protein.

OUTCOME AND FOLLOW UP:
Laboratory testing revealed normal metabolic panel,
hepatic function panel, cell counts with differential, and
inflammatory markers. An echocardiogram revealed
normal left ventricular function without evidence of
valvular disease or pulmonary hypertension.
A CT of the thorax revealed absence of consolidation,
mass, and lymphadenopathy. There was no pleural
effusion. There was an area of slightly improved scarring
in the right lung base, accounting for the abnormal right
lower lobe finding on plain chest radiography (Figure 4).
Pulmonary function testing revealed slight restrictive
physiology with a decreased diffusion capacity that
corrected when adjusted for volume loss caused by right
lower lobe scarring.
Our hypothesis was that the patient suffered from Rosai
Dorfmann disease in 2010 and that her biopsies and
esophageal perforation caused the observed x-ray and
CT findings that are stable to this current evaluation. As
the patient’s pulmonary workup was benign, she was
encouraged to undergo further cardiac workup, including
stress testing.

KEY POINTS:
Sinus histiocytosis with massive lymphadenopathy
is primarily a benign proliferation of monocytes in
macrophages that typically affects the cervical lymph
nodes in children and young adults. It typically involves a
self-limiting clinical course that rarely requires treatment.
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DISCUSSION:
Sinus histiocytosis with massive lymphadenopathy
is primarily a benign proliferation of monocytes and
macrophages that affects the cervical lymph nodes in
children and young adults. Here we present a case of a
61-year-old female with mediastinal lymphadenopathy
and histologic changes suggestive of SHML.
Review of the literature reveals several case reports of
more typical SHML. Most patients not only present with
painless, enlarged, cervical lymph nodes but may also
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receiving surgical debulking and systemic treatment with
corticosteroids or chemotherapy only when organ systems
become compromised.
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Sudden Vision Loss During Hemodialysis
Andrew W. Panakos, MD

INTRODUCTION
Catheter-related blood stream infections (CRBSIs) are a
common and unfortunate consequence of prolonged
vascular access in hemodialysis patients. Metastatic
infections are feared sequelae of bacteremia, and
include endocarditis, osteomyelitis, septic arthritis,
epidural abscess, and endophthalmitis.1 The following
is a case of Serratia endophthalmitis originating from a
tunneled-dialysis catheter.

CASE PRESENTATION
A 47 year-old Caucasian female with a history of end
stage renal disease on hemodialysis, Type 2 diabetes
mellitus, and hypertension was undergoing her routinely
scheduled hemodialysis session when she experienced
“flashes of hot pink” in her left eye. The hemodialysis
session was terminated, and the patient returned home.
When she awoke the next morning she noticed a large
black spot obscuring vision in her left eye as well as pain
in the affected eye. The patient presented to Wills Eye
Emergency Department that day. She denied any recent
fevers, chills, pain, or erythema at the catheter site. She
did, however, report that her left-sided chest wall tunneled
dialysis catheter had been manipulated and tubing had
been exchanged the day prior because of concerns that
it was clogged. The patient was transferred to Thomas
Jefferson University Hospital (TJUH) for further care.
Initial vital signs revealed a temperature of 98.6 degrees
Fahrenheit, heart rate of 88 beats per minute, respiratory
rate of 21 per minute, blood pressure of 160/94 mmHg,
and 95% oxygen saturation on room air. Physical exam
was significant for a diffusely erythematous left sclera
with a hazy cornea and a small hypopion occupying the
bottom third of the pupil (Figure 1). Her left pupil was
sluggishly reactive to light. The patient’s visual acuity
exam of the left eye revealed 20/60 vision (20/20 in right
eye). Her left chest wall port site was non-erythematous
with no palpable fluctuance or drainage. There was no
tenderness to palpation in this area. Cardiac exam revealed
a grade II/VI systolic ejection murmur most prominent
at the right upper sternal border. There were crackles at
both lung bases and bilateral 2+ lower extremity pitting
edema to the shins. There were no splinter hemorrhages

Figure 1. Patient’s eye exam on day 3 of hospitalization, revealing
significant hypopion and haziness of the cornea.

or other skin changes. The patient’s admission laboratory
values were notable for a white blood cell count of 16,200
cells/microliter (normal range 4,000-11,000) with 92%
neutrophils (normal range 40-73%) and a hemoglobin of
7.5 g/dl (normal 12.5-15) decreased from a baseline of
9 g/dl. A chest x-ray was normal.

DIFFERENTIAL DIAGNOSIS
The differential diagnosis for sudden vision loss is
broad and can be divided into media disruptions, retinal
problems, and neural visual pathway disturbances.
Examples of media problems include keratitis, hyphema,
lens changes, vitreous hemorrhage, uveitis, and
endophthalmitis. Retinal pathology includes vascular
occlusion, retinal detachment, and acute macular
problems. Neural visual pathway disruptions can involve
the optic nerve, chiasm, and retrochiasm.2
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Figure 3. Structures of the eye. Endogenous endophthalmitis gains
access to the eye through the choroid, the blood supply to the retina.
http://www.harcourtcarteroptical.com/content2/anatomy

Figure 2. Patient’s eye 7 days after admission. Notable are
increased swelling, pus, worsening hypopion.

OUTCOME AND FOLLOW-UP
The patient’s indwelling central venous access, elevated
white blood cell count, and physical exam findings
raised suspicion for an infectious cause of vision loss. A
culture of the patient’s vitreous fluid resulted as “many
gram negative coccobacilli” five hours after being
drawn, virtually clinching the diagnosis of bacterial
endophthalmitis. The final culture revealed Serratia
marcescens. Blood cultures drawn upon admission to
TJUH grew gram negative bacilli one day after collection,
and subsequently also speciated as Serratia marcescens.
An ultrasound of the eye, also known as a “B scan”,
was performed by Ophthalmology and showed a large
subretinal abscess and dense vitritis.
Her tunneled dialysis catheter was kept in place for
48 hours to allow her to receive two more dialysis
sessions due to concern for refractory fluid overload.
Subsequently, the catheter was removed and she was
given a three day line holiday before replacement once
her blood cultures had cleared. Of note, cultures from
the catheter tip also grew gram negative bacilli.
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The patient was noted to have a systolic ejection murmur
upon admission. It was unknown whether this was a new
finding. Considering her evidence of metastatic infection,
endocarditis was a concern (particularly involving the
aortic valve). However, a transthoracic echocardiogram
revealed no abnormalities involving the aortic valve or
other vegetations. The patient’s murmur resolved with
red blood cell transfusion, thus it was felt that her initial
murmur was a flow murmur related to anemia.
The patient was initially treated broadly with intraocular
vancomycin, ceftazadime, moxifloxacin, and prednisolone,
as well as intravenous vancomycin and piperacillintazobactam. Oral moxifloxacin was added on day 3 for
its vitreal penetration. Intravitreal tobramycin and atropine
eye drops were also added on day 5. Sensitivities returned
and subsequently the patient’s non-ocular antibiotics
were de-escalated to only oral ciprofloxacin.
Despite these interventions, the patient suffered
progressive vision loss and eye swelling (Figure 2). Oral
prednisone was added but did not significantly improve
her ocular symptoms. Ten days after presentation,
the patient underwent enucleation of her left eye for
progressive swelling, pain, and fear of refractory ocular
infection which could spread beyond the orbit. An ocular
implant was inserted during the same surgery. She was
discharged on both oral and ocular ciprofloxacin as well
as ocular moxifloxacin and a Medrol dose pack.

DISCUSSION

KEY POINTS

The most important modifiable risk factor for tunneled
CRBSI is duration of catheter usage.3 One study found
a 35% and 48% incidence of CRBSI at three and six
months, respectively. 3 The type of vascular access
for hemodialysis patients also has an effect on the
risk of infection. The relative risk of blood stream
infection of a tunneled dialysis catheter compared
with an arteriovenous fistula is 10:1. Additionally, the
relative risk of a non-tunneled vs. tunneled dialysis
catheter is 3:1.3 Other risk factors for CRBSIs include
previous CRBSI, recent surgery, diabetes mellitus, iron
overload, immunosuppression, and hypoalbuminemia.3
Five techniques recommended by the Institute for
Healthcare Improvement to prevent primary blood
stream infections include effective hand hygiene,
maximal barrier precautions at insertion, cutaneous
antisepsis with chlorhexidine, optimal insertion site
selection, and prompt removal when the catheter is no
longer necessary.5 Microorganisms reach circulation
in one of three ways: 1) colonization of insertion site
(most common), 2) colonization of hubs, junctions, and
other connectors—with subsequent access when these
are manipulated, and 3) contamination of infused fluid.5

Catheter related blood stream infections are a common
and often avoidable occurrence. The incidence of
CRBSIs in end stage renal disease patients is directly
related to the amount of time the catheter is left in
place. CRBSIs should be suspected in any patient
with central venous access who presents with fevers/
chills or any signs of metastatic infection. Endogenous
endophthalmitis is a potential metastatic manifestation
of a CRBSI. Urgent ophthalmic consultation, intraocular
and systemic antibiotics/antifungals, as well as catheter
removal are the mainstays of treatment.

Endophthalmitis is a potential metastatic complication
of CRBSIs. Endophthalmitis refers to a bacterial or
fungal infection within the eye, including involvement
of the vitreous and/or aqueous humors. 4 Of note,
endophthalmitis is not caused by viruses or parasites; eye
infections due to these organisms are termed “uveitis”.
Endophthalmitis is further divided into exogenous and
endogenous causes. Exogenous endophalmitis refers
to infections that occur due to external factors such as
trauma, surgery, or corneal infection. These account for
the majority of cases of endophthalmitis. In contrast,
endogenous endophthalmitis occurs due to seeding
of the eye from within the body, typically through the
choroid, which supplies blood to the retina.
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The Rare Case of Streptococcus Pyogenes
Pneumonia and Its Sequelae
Fern Martin, MD and Gloria Francis, MD

INTRODUCTION

INVESTIGATIONS AND TREATMENT

Group A Streptococcus (GAS) or Streptococcus pyogenes
is an aerobic gram-positive coccus that causes a
multitude of infections that range in severity. GAS most
commonly infects the soft tissues, which results in
infections such as cellulitis, erysipelas, necrotizing fasciitis
and myositis. These deep soft tissue infections are also
the most common source of GAS bacteremia. Other
common infections caused by GAS include pharyngitis,
rheumatic fever and glomerulonephritis.1 The lower
respiratory tract is an uncommon site for GAS infection
and it is the least common source of GAS bacteremia;
however, in adults with GAS pneumonia, the incidence of
bacteremia is 80 percent.2 Patients with a severe GAS
infection can develop streptococcal toxic shock
syndrome, which consists of GAS bacteremia in
conjunction with shock and organ failure. Here we
present a case of severe GAS pneumonia complicated by
toxic shock syndrome and purpura fulminans, a rare
complication of disseminated GAS infection.

After fluid resuscitation and antibiotic initiation, the
patient’s vital signs improved to a heart rate of 102 bpm
and blood pressure of 116/72 mmHg. On hospital day 2,
the patient had a temperature of 103.1° F, heart rate 108
bpm, blood pressure 91/60 mmHg, respiratory rate 35
bpm, and pulse oximetry of 90% on a non-rebreather. The
patient was intubated for acute hypoxic respiratory failure.
His rapid influenza test was negative and gram stain from
blood cultures revealed gram-positive cocci in chains.
The team presumed that the patient had a Streptococcus
species pneumonia with subsequent bacteremia.
Over the next twelve hours, the patient continued to
be hypotensive and a norepinephrine infusion was
started. He subsequently developed acute oliguric renal
failure, which required hemodialysis. Blood cultures
grew Streptococcus pyogenes, but despite appropriate
intravenous (IV) antibiotics and vasopressors, the patient
remained hypotensive and his lactate rose to 12.2 mmol/L.
On hospital day 3, his bilateral dorsalis pedis, posterior
tibialis, and left radial pulses were absent. He developed
areas of ecchymoses on his lower extremities that evolved
into indurated, well-demarcated purple papules with
erythematous borders. The patient was diagnosed with
purpura fulminans given his vascular thromboses and
disseminated intravascular coagulopathy. He was started
on clindamycin and given a dose of intravenous immunoglobulin for presumed toxic shock syndrome secondary to
GAS bacteremia. His overall status continued to worsen, as
he developed ischemic limbs, shock liver and worsening
mental status. Vascular surgery was emergently consulted
and felt the patient would require amputations of all
distal extremities if he were to recover hemodynamically.
On hospital day 5, the patient’s pupils were minimally
responsive and he had temperatures of 107° F. It was felt
the patient had a cerebral event and a CT scan of the head
was ordered. He had a witnessed seizure in the radiology
department and developed atrial fibrillation that ultimately
became asystole. No cardiopulmonary resuscitation (CPR)
was initiated as the patient was made do not resuscitate
(DNR) by his family. The patient was pronounced dead in
the MICU, and his family was notified.

CASE PRESENTATION
A 57-year-old male with a history of gastric adenocarcinoma
status post partial gastrectomy presented with a two-day
history of shortness of breath and chest tightness. He
denied any associated fevers, cough, sputum production,
pharyngitis, diarrhea or dysuria. In the emergency room, he
was afebrile (although he had been taking acetaminophenoxycodone tablets every 4 to 6 hours for his chest pain)
with a heart rate of 123 bpm, blood pressure 78/49 mmHg,
respiratory rate 21-27 bpm, and pulse oximetry of 94%
on a non-rebreather. Physical exam revealed right upper
lobe rales, as well as egophony and sinus tachycardia.
There was no evidence of pharyngeal erythema, exudates,
or ulcers. Pertinent lab work on admission included a
creatinine of 2.3 mg/dL and a lactate of 9.0 mmol/L.
Computed tomography (CT) of his chest was consistent
with pneumonia in the right upper lobe with patchy areas
of consolidation in the right middle and lower lobes. The
patient received ceftriaxone, azithromycin and five liters of
normal saline. He was admitted to the medical intensive
care unit (MICU) for severe sepsis secondary to communityacquired pneumonia.
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DISCUSSION
GAS is an aerobic gram-positive beta-hemolytic coccus
that causes an array of diseases in all age groups. In
patients over the age of forty, risk factors for developing
GAS bacteremia include burns, surgical procedures,
trauma, nosocomial transmission, chronic steroid use,
cardiac disease, diabetes mellitus, peripheral vascular
disease, malignancy and immunosuppression3,4. Early
recognition of GAS bacteremia is important to improving
survival. GAS bacteremia can lead to shock and organ
failure, such as renal failure, acute respiratory distress
syndrome, hepatic failure and diffuse capillary leak
syndrome.1 Streptococcal toxic shock syndrome (TSS)
can be caused by any streptococcal species, but it is
most commonly associated with GAS.5 The mortality
rate for patients with GAS bacteremia is approximately 35
percent; however once TSS develops, the mortality rate
is 79 percent.6
In addition to aggressive fluid resuscitation, GAS TSS must
also be treated with IV antibiotics. GAS is susceptible to
beta-lactam antibiotics, but there is a high failure rate in
invasive infections.7 Beta-lactams, such as penicillin G,
inhibit cell wall synthesis, but can be overwhelmed by
a large inoculum size. Clindamycin should be added
to the antibiotic regimen to suppress toxin production
by inhibiting protein synthesis.8 Intravenous immune
globulin (IVIG) can also be used as an adjunctive therapy.
Though data on using IVIG in patients with streptococcal
TSS is limited, it is believed that IVIG helps by raising
antibody levels in patients with invasive infections. 8 A
study conducted by Carapetis et al. examined eighty-four
patients with invasive GAS infections. The primary
outcome of mortality was compared across patients who
received clindamycin as a single adjunct versus patients
who received dual adjunct therapy with clindamycin and
IVIG.8 Patients treated with clindamycin often had more
severe disease but lower mortality (15% versus 39%).8
Patients who received IVIG in addition to clindamycin had
an even lower mortality rate, at 7%.8
Our patient presented with common features of GAS
TSS, including shock and multi-organ failure, as well
as rarer manifestations, such as purpura fulminans and
limb ischemia. Purpura fulminans is most commonly
seen in children with invasive group B beta-hemolytic
streptococcal infections,9 but it has also been reported
in association with GAS.10 In adults, purpura fulminans is
most commonly associated with Neisseria meningitidis,
followed by streptococcal species.11 In asplenic adults,

purpura fulminans is associated with Streptococcus
pneumoniae bacteremia.12 It can also occur in individuals
with inherited or acquired deficiencies in the Protein C
or Protein S anticoagulant pathway.13 Purpura fulminans
is rarely reported in adults with GAS bacteremia who
have functioning spleens. Purpura fulminans is a severe,
life-threatening syndrome in which disseminated
intravascular coagulation (DIC) leads first to hemorrhagic
skin infarcts and progresses to limb ischemia. When
purpura fulminans is due to sepsis, the vascular lesions
causing the classical skin findings also involve a variety of
organs, including the kidneys, lungs, and adrenal glands.
The mortality rate associated with purpura fulminans is
typically greater than 50 percent.11
The pathogenesis of sepsis-induced purpura fulminans
involves bacterial endotoxin mediated disturbances of
procoagulant and anticoagulant activities in vascular
endothelial cells. Anticoagulant factors become widely
consumed, leading to a state of DIC.14 The initial clinical
manifestation of purpura fulminans is typically a petechial,
purpuric rash. Other clinical features include the classical
manifestations of sepsis, such as fevers and hypotension.
The characteristic petechial rash typically develops 12-24
hours after onset of infectious symptoms, which in the
above patient included shortness of breath and chest
tightness. As hemorrhagic skin infarction progresses,
the petechiae coalesce to form purpuric ecchymoses.
Hemorrhagic bullae can then form and develop into dry
gangrene.15
Treatment is mainly supportive and also targets the
bacterial trigger of purpura fulminans.11 The majority of
affected patients require intensive care unit monitoring
for aggressive fluid resuscitation, inotropic support,
mechanical ventilation, and/or hemodialysis. Surgery
can be performed to debride necrotic tissue, but most
affected patients eventually require amputations of
ischemic limbs.16 Various therapies have been proposed
to target the coagulation pathway deficiencies associated
with purpura fulminans, but none have showed any
significant clinical efficacy. 11 Recombinant activated
protein C has been described as a promising adjunctive
therapy in a number of case studies and retrospective
studies; however, no randomized controlled trials have
been performed to demonstrate its effectiveness.17
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Tumor Lysis Syndrome in Light Chain Multiple Myeloma
Treated with Bortezomib Combination Therapy
Hasmik Minasyan, MD* and Meaghan Henrici, MD*
*First authors

INTRODUCTION
Tumor lysis syndrome (TLS) is a potentially life threatening
complication of cancer treatments that typically occurs
in highly proliferative malignancies. It is rare in patients
with multiple myeloma (MM) given the disease’s indolent
nature and is estimated to occur in less than 1% of cases.1
Increasing reports of TLS have been described in MM,
particularly in treatment regimens containing bortezomib,
the first available proteasome inhibitor. Here we describe
a case of a newly diagnosed light chain multiple myeloma
resulting in tumor lysis syndrome following the first dose
of combination therapy with bortezomib, cyclophosphamide and dexamethasone.

CASE REPORT
A 68 year old man presented with 6-8 weeks of gradually
worsening lower back pain and fatigue. In addition, he
reported symptoms of severe constipation, nausea, night
sweats, dysuria, right sided rib pain, and a 30 lb weight
loss. On examination, he had tenderness to palpation
along the lower thoracic spine, para-spinal muscles
and lower anterior ribs bilaterally. He was found to
have deranged renal function with a serum creatinine
of 2.75 mg/dl, corrected serum calcium of 11.9 mg/dl,
macrocytic anemia with hemoglobin of 11.4 g/dl (MCV
102) and urinalysis with trace protein but a urine protein
to creatinine ratio of 9.6. The liver function tests were
normal. An X-Ray of his thoracic and lumbar spine
revealed a T12 compression fracture.
Subsequent labs revealed hypogammaglobulinemia and
beta-2 microglobulin elevation of 19.53 mg/L (normal
1.31-2.6 mg/L). Serum protein electrophoresis had a
monoclonal lambda light chain spike measuring 14,520
mg/L. 24 hour urine studies showed 11.5g of protein
and 12.1g lambda light chains. A skeletal survey showed
a questionable lucent lesion in the right 10th posterior
rib. He underwent a bone marrow biopsy which showed
45.9% plasma cells. FISH probe was negative for common
cytogenetic abnormalities including 13q deletion. The
patient was diagnosed with lambda light chain multiple
myeloma, International Staging System (ISS) stage III.

For treatment, the day 1 cycle included bortezomib
1.3mg/m2, cyclophosphamide 300mg, and dexamethasone
40mg. Prior to starting chemotherapy, his serum
creatinine had improved to 2.5 mg/dL with normal serum
electrolytes. Calcium remained elevated at 11.2mg/
dL despite hydration. His care was transferred to the
Veteran’s Hospital’s Community Living Center for the
duration of his chemotherapy.
24 hours after his first dose of chemotherapy, he
re-presented to the emergency room with hypoxia,
hypotension, tachycardia, and tachypnea. No fever
was observed. Initial laboratory values were as follows:
potassium 5.5 mmol/L, serum uric acid 22.7 mg/dL,
serum phosphorous 8.2mg/dL, bicarbonate 20mmol/L
with anion gap of 17, serum calcium 8.3mg/dL, lactate
1.7mmol/L, LDH 1147 IU/L, and serum creatinine 3.41
mg/dL. He met clinical and laboratory criteria for tumor
lysis syndrome (TLS) based on the Cairo-Bishop definition
(Table 1). For TLS treatment the patient was started on
IV fluid hydration with bicarbonate supplementation,
allopurinol 200 mg daily and given a dose of raspuricase
0.15 mg/kg. The patient was admitted to the ICU and
closely monitored.
TABLE 1: CAIRO-BISHOP DEFINITION OF TUMOR LYSIS
SYNDROME (TLS) IN ADULTS
Laboratory TLS: ≥2 of the following serum
abnormalities, developing within 3 days before or
7 days after initiation of chemotherapy
-Uric acid ≥ 8 mg/dL or 25% increase from baseline
-Potassium ≥ 6 meq/L or 25% increase from baseline
-Phosphorous ≥ 4.5 mmol/dL or 25% increase from
baseline
-Calcium ≤ 7 mg/dL or 25% decrease from baseline
Clinical TLS: Laboratory TLS AND ≥1 of the
following criteria
-Creatinine >1.5x upper limit of normal
-Cardiac arrhythmia or sudden death
-Seizure
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DIFFERENTIAL DIAGNOSIS
Differential diagnosis of new onset lower back pain in
this elderly man included multiple myeloma, metastatic
prostate cancer, lumbar strain, hyperparathyroidism
and severe constipation secondary to an underlying
malignancy of the colon.

OUTCOME AND FOLLOW UP
Over the course of several days, the patient’s TLS
labs normalized and he was discharged back to the
Veteran’s Community Living Center for rehabilitation. Per
oncology’s recommendation, he was treated again with
bortezomib, cyclophosphamide and dexamethasone. He
was re-admitted to the hospital approximately 2 weeks
later with altered mental status and dehydration. Tumor
lysis labs at this time were normal. During this hospitalization, the patient and his family made the decision to
withhold further treatment and enter home hospice.

DISCUSSION
Tumor lysis syndrome (TLS) is a complication carrying a
high morbidity and mortality most commonly occurring
secondary to cell lysis caused by chemotherapy with the
subsequent release of intracellular potassium, phosphate,
and nucleic acids into the bloodstream. Characteristic
laboratory findings include hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia and elevated
LDH. Clinically, patients can present with nondescript
symptoms such as nausea and vomiting, or life
threatening cardiac arrhythmias, renal failure, seizures,or
sudden death. TLS is most frequently associated with
highly proliferative neoplasms such as non-Hodgkins
lymphoma and acute lymphocytic leukemia, while
plasma cell dyscrasias such as multiple myeloma are
classified as typically having a <1% risk.1
Multiple myeloma is characterized by a low proliferative
index with less than 1% plasma cells engaging in cellular
proliferation.2 As a result, TLS is a rare complication of
chemotherapy in the treatment of multiple myeloma. It
is believed to have a higher likelihood of occurrence in
patients with a high tumor burden, especially if treated
with bortezomib in combination with other agents. The
definition of high tumor cell burden is not clear in the
literature, but it is believed to be correlated with increased
serum lactate dehydrogenase and Beta-2 microglobulin
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levels (≥ 5.5 mg/dL) as well as diffuse bone marrow
disease, multiple lytic lesions, hypercalcemia (>12 mg/dL)
and positive C reactive protein.8 TLS has also been cited
to occur in monotherapy treatment with bortezomib,
steroids, or thalidomide.2 Additional risk factors associated
with the development of TLS in multiple myeloma
include high proliferative activity, immature plasma cell
morphology, and poor cytogenetics.2,3,4 Case reports by
Hung Chang et al associate higher rates of TLS in light
chain myeloma with pre-existing renal insufficiency prior
to chemotherapy, a presentation similar to our patient.
Nonetheless, not enough data exists to have clear
understanding of the risk factors and whether certain
types of multiple myeloma carry a higher risk.
Since the introduction of bortezomib, there have been
several other case reports of patients with multiple
myeloma developing tumor lysis syndrome with a
reported incidence of 1.4%.3 As a reversible inhibitor of the
26S proteasome, bortezomib’s impact on the transcriptional factor NF-kB is thought to be the mechanism of
rapidly induced cancer cell apoptosis.3 In a case series,
Sezer et al. reviewed 496 cases of multiple myeloma
treated with bortezomib in three phase II multi-center
trials and found that the criteria for tumor lysis syndrome
was fulfilled in 7 cases (1.8%). TLS caused renal failure
leading to dialysis occurred in three cases, with one patient
subsequently dying from renal failure. When a timeline
was explicitly described, the earliest TLS case occurred
on day 5 following bortezomib administration, making
our patient’s presentation one day after treatment even
more atypical. Additionally, in two of the cases, TLS did
not occur on initial exposure to bortezomib, but rather
during retreatment with bortezomib in combination with
dexamethasone.6
Since the majority of reported cases of TLS typically occur
very early in the course of treatment with bortezomib,
patients are at the highest risk during the first cycle of
therapy. Therefore, it is important to closely monitor
patients receiving bortezomib, particularly those with
higher tumor burden. Concomitant use of thalidomide
or dexamethasone, such as in our patient, tends to
increase the likelihood of tumor lysis syndrome.5 Chim
in his article suggests TLS prophylaxis with hydration and
alkalinization in patients with a high tumor burden who
are being started on a treatment with bortezomib.

CONCLUSION
Although rare, tumor lysis syndrome (TLS) is a potentially
severe complication in the treatment of multiple
myeloma. After initiation of treatment, patients should
be closely monitored, particularly those with a high
tumor burden receiving bortezomib. There is a need for
further studies and case reports to identify incidence and
predicting factors that may lead to TLS in patients treated
for multiple myeloma.
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Hemorrhagic Bullous Dermatosis
Bhuvanesh Govind, MD, Luis Eraso, MD, Esteban Gnass, MD, Geno Merli, MD

Figure 1. Hemorrhagic Bullosis Dermatosis. Well-circumscribed,
tense, nontender bullae with no significant surrounding erythema.
Figure 2. Intraepidermal collection of red blood cells, beneath the
keratin layer. (4x power)

The patient is a 64 year old man with active primary central
nervous system B-cell lymphoma who was hospitalized
for management of a right lower extremity traumatic injury
complicated by a calf hematoma. During the hospital
stay, the patient was diagnosed with a provoked left
lower extremity deep vein thrombosis (DVT) and treated
initially with therapeutic dosing of enoxaparin. Five days
after low molecular weight heparin (LMWH) initiation,
gradual development of tense, well-circumscribed bullae
were noted to appear on his arms and hands bilaterally,
ranging from 0.5 cm to 1.5 cm in diameter. These lesions
were both nonpruritic and nontender with no significant
surrounding erythema (Figure 1). Bullae were located
distal to the site of enoxaparin injections. Aside from a
normocytic normochromic anemia related to chronic
medical conditions, results of platelet counts, creatinine
levels, and coagulation profiles remained unremarkable.
A shave biopsy of one of the lesions revealed an intraepidermal collection of red blood cells without evidence
of thrombotic or vasculitic changes (Figures 2 & 3).
enoxaparin dose was reduced several days after lesion
onset due to increasing calf hematoma size, in an effort
to balance anticoagulation benefit for the DVT with risk
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Figure 3. No evidence of thrombotic or vasculitic changes.
Hemorrhagic collection with occasional neutrophils. (210x power)

of continued bleeding into the hematoma. The bullae
started to regress approximately two weeks after onset,
eventually crusting over. The patient was eventually
discharged home.
We present a case of hemorrhagic bullous dermatosis,
which is a rare type of cutaneous reaction to heparins
with only a handful of cases reported in the literature.
Delayed-type (type IV) hypersensitivity and immunemediated (heparin-induced thrombocytopenia)
mechanisms are the most common causes of cutaneous
complications attributed to heparin products.1 Type IV
cutaneous hypersensitivity reactions are non-antibody
mediated and typically occur several days to weeks
following drug exposure. They may manifest as isolated
or multiple erythematous plaques with papulovesicles
or scaling. Heparin-induced thrombocytopenia, on the
other hand, can induce skin erythema that progresses
to hemorrhage and subsequent tissue necrosis.1 Several
unusual and rare dermatologic manifestations have
been reported in the literature with a broad differential
diagnosis including pustulosis, toxic epidermal
necrolysis, arthus reaction, baboon syndrome, hypereosinophilia, and calcinosis cutis.1,3
There have only been ten cases reported in the
literature regarding the clinical setting and course of
hemorrhagic bullosis. Mechanisms underlying the
pathogenesis of these lesions have not been clearly
elucidated, although a hypersensitivity reaction has
been suspected.1,4,5 The histopathology of the bullae
reveal intraepidermal collections of red blood cells
without any thrombotic or vasculitic changes. Direct
immunofluorescence and heparin platelet factor 4 have
all been negative in prior case reports.4-7 Only one of
the ten cases has reported unfractionated heparin as
an inciting agent for hemorrhagic bullosis,8 while the
remaining have been from LMWH. The age range of
affected patients in case reports were 50-90 years old
with several having a history of malignancy.4-8

heparin therapy with no changes in dosing. Although the
resolution of bullae in our patient occurred several days
after enoxaparin dose reduction, it is hard to differentiate
whether lesion regression occurred directly due to
medication management or the natural history of these
seemingly benign, self-limiting, bullae.
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Hemorrhagic bullosis seems to take a clinically benign
course with no patient report of pain or pruritis. The onset
of bullae in our case is consistent with the reported 5 to
21 day window of lesion development reported in the
literature. The association between lesion regression
and discontinuation of heparin treatment seems to
be unclear given that about half of the patients’ bullae
reported thus far regress despite continuation of
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Pneumothorax ex vacuo in a Patient with Malignant
Pleural Effusion After PleurX Catheter Placement
Meera Bhardwaj, MS4 and Loheetha Ragupathi, MD

INTRODUCTION
Pneumothorax ex vacuo (“without vaccuum”) is a type
of pneumothorax that can develop in patients with
large pleural effusions. Unlike spontaneous or tension
pneumothoraces, pneumothorax ex vacuo does not
require chest tube placement. Careful recognition of this
type of pneumothorax may save patients and physicians
from an unnecessary procedure, and limit patient risk of
infection, bleeding and further lung injury.

CASE REPORT
An 81 year old woman with a history of osteoarthritis,
depression, and remote smoking history, presented to
her primary care provider complaining of progressive
cough, dyspnea, and 30 lb unintentional weight loss. An
outpatient chest radiograph revealed total opacification
of the right lung. She was admitted to the hospital
for further management. Computed tomography
showed a large right pleural effusion with partial
collapse of the right lung, bilateral pulmonary nodules,
and obliteration of the right lower lobe bronchus. A
diagnostic thoracentesis showed an exudative effusion,
and cytology was consistent with primary lung adenocarcinoma. Bronchoscopy revealed an aerated right upper
lobe, and endobronchial biopsy was unrevealing.
Due to worsening hypoxia, a PleurX drainage catheter
was placed, and one liter of pleural fluid was removed
daily. Lungs were monitored with post-drainage
radiographs, and the patient improved clinically. Five
days after PleurX placement, however, she was noted
to develop right upper lobe atelectasis and a right apical
pneumothorax with no tracheal deviation (Figure 1). In the
setting of collapsed lung due to sudden atelectasis, this
represented pneumothorax ex vacuo. Her management
continued unchanged and she was safely discharged to
a rehabilitation facility with pneumothorax ex vacuo and
PleurX catheter in place.
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Figure 1. Portable chest radiograph demonstrating right
upper lobe atelectasis (white arrow head) with pneumothorax
ex vacuo (white arrow), in the setting of right pleural effusion
and right-sided PleurX catheter.

Pneumothorax ex vacuo: A pneumothorax ex vacuo
was traditionally thought to develop when a mucus
plug, foreign body, or extrabronchial mass obstructs
a bronchus causing acute lobar collapse. The sudden
lobar collapse generates a negative intrapleural pressure
that draws gas—mainly nitrogen—from the neighboring
tissues and blood into the adjacent pleural space.1 More
recently, pneumothorax ex vacuo is also thought to
develop when a lung is unable to re-expand following
drainage of pleural fluid.2,3 The seal between the visceral
and parietal pleura remains intact at the sites of the
aerated lobes, causing the pneumothorax ex vacuo to
surround only the collapsed lobe, distinguishing it from
both tension and spontaneous pneumothoraces.1 Boland
et al.2 and Ponrartana et al.3 demonstrate that chest
tubes are not beneficial for asymptomatic patients with
malignant lung parenchymal disease and pneumothorax
ex vacuo. Malignant infiltration of the lung tissue leads
to poor lung compliance and unresponsiveness to chest
tubes.2 One hypothesis is that malignant cells create a
fibrinous peel limiting re-expansion of the lung, while

another suggests that chronic atelectasis, interrupted
blood flow, and pulmonary edema decrease production
of pulmonary surfactant prohibiting lung re-expansion
after pleural fluid drainage.3 Observation is appropriate
and sufficient in asymptomatic patients.2,3 If there is
concern for trapped lung, Pien et al. found that PleurX
catheter placement is an effective treatment.4
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KEY POINTS:
Pneumothorax ex vacuo develops in the setting of
sudden acute lobar collapse, and persists from an
inability of the lung to re-expand. Unlike tension or
spontaneous pneumothoraces, it only surrounds the
atelectatic lobe and does not surround the lobe(s)
that are healthy and aerated.1 Unlike spontaneous and
tension pneumothoraces, pneumothorax ex vacuo
should be observed without chest tube placement in
the asymptomatic patient.2,3
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